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TB patients show poor compliance to available drugs due to the costs, adverse side effects, and 
prolonged treatment, leading to multi-drug resistant (MDR), extensively drug resistant (XDR), 
and most recently totally drug resistant TB. Shared drug toxicities and drug interactions with 
antiretrovirals compound the problem. The rapid development of resistance to known 
antimalarials compared to the rate at which new agents are coming into the market still 
remains a big challenge is combating malaria. Currently, with resistance to ACTs having been 
documented in South-East Asia, the situation is dire as there is no ready alternative to these 
drugs. There is thus a heightened need for research towards the development of new anti-TB 
and anti-malarial drugs based on novel chemotypes. Towards addressing this need, SAR studies 
were conducted on the 2-amino-4-aryl thiazole scaffold by synthesizing a series of derivatives 
with different motifs at the various positions of the scaffold. These derivatives exhibited 
moderate antiplasmodial activity in the CQS strain of P. falciparum, and good antimycobacterial 
activity on the H37Rv strain of M.tb. A 2-pyridyl group at position 4 of the thiazole ring as well 
as a substituted phenyl at position 2 was found to be essential for antimycobacterial activity. 
However, the 2-pyridyl group was not essential for antiplasmodial activity while the substituted 
phenyl at position 2 was essential for antiplasmodial activity. The linker between these two 
groups affected antimycobacterial activity with little influence on the antiplasmodial activity. In 
addition structural modifications were performed on the ergoline backbone of metergoline, 
and a number of derivatives synthesized with different para substituted phenyls. These 
compounds exhibited moderate antiplasmodial activity in the CQS strain of P. falciparum, and 
moderate antimycobacterial activity on the H37Rv strain of M.tb. The presence of a substituted 
phenyl group attached to the nitrogen atom of the amine was found to be essential for 
antimycobacterial activity, however, this substituted phenyl group didn’t confer optimum 
antimycobacterial activity as the compounds were less active than metergoline. The 
antiplasmodial activity of these compounds was better than that of metergoline and was 












between the ergoline backbone and the substituted phenyl ring didn’t have any significant 







































°C                     degree celsius 
µg/Ml              microgram per milliliter 
µM                   micro molar 
ACTs                Artemisinin Combination Therapies 
ADME             Absorption, Distribution, Metabolism, Excretion 
AIDS                Acquired Immuno Deficiency Syndrome 
Br2                   bromine 
CDC                 Centre for Disease Control 
CDCl3               deuterated chloroform 
CHO                 Chinese Hamster Ovarian 
CQ                   Chloroquine 
CQS                 Chloroqiune Sensitive 
DAD                 Diode Array Detector 
DCM                dichloromethane 
DMF                N, N-dimethylformamide 
DMSO             dimethyl sulfoxide 
DMSO-d6        deuterated dimethyl sulfoxide 
DOT                 Directly Observed Therapy 
EDCI                1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EMB                Ethambutol 
EtOAc              ethyl acetate 
EtOH                ethanol 
HBr                  hydrobromic acid 
HIV                  Human Immunodeficiency Virus 
HLM                Human Liver Microsomes 
HOBt               N-hydroxybenzotriazole 
HPLC               High Performance Liquid Chromatography 
Hr                    hour 
HTS                  High Through-put Screen 
IC50/IC90         inhibitory concentration required to inhibit the growth of 50%/90% of organisms 
IM                    intramuscular 
INH                  Isoniazid 
IV                     intravenous 
KCl                   potassium chloride 
LRMS               Low Resolution Mass Spectroscopy 
LTBI                 Latent Tuberculosis Infection 
M.tb                Mycobacterium tuberculosis 
M/Z                 mass to charge ratio 
MDR                Multi-Drug Resistant 
MeOH             methanol 












MHZ                     Megahertz 
MIC90/MIC99       minimum inhibitory concentration which inhibits growth of 90%/99% organisms  
MLM                   Mouse Liver Microsomes 
MS                       Mass Spectroscopy 
MTT                     3-(4, 5-dimethylthiazol-2-yl)-2, 5- diphenyltetrazoliumbromide 
Na2SO4                sodium sulphate 
NaCl                    sodium chloride 
NADPH                Nicotinamide Adenine Dinucleotide Phosphate 
NaHCO3               sodium hydrogen carbonate 
NaOH                  sodium chloride 
NIH                      National Institute of Health 
nM                       nano molar 
NMR                    Nuclear Magnetic Resonance 
PBS                      Phosphate Buffered Saline 
Pd/C                    palladium on carbon 
ppm                     parts per million 
PZA                      Pyrazinamide 
QSAR                   Quantitative Structure Activity Relationship 
RIF                       Rifampicin 
RLM                     Rat Liver Microsomes 
RT                        Room Temperature 
SAR                      Structure Activity Relationship 
SI                          Selectivity Index 
TAACF                 Tuberculosis Antimicrobial Acquisition and Coordinating Facility 
TB                        Tuberculosis 
TDR                     Total-Drug Resistance 
THF                      tetrahydrofuran 
TLC                      Thin Layer Chromatography 
TMS                    Tetramethylsilane 
tr                                      retention time 
WHO                   World Health Organization 
XDR                     Extensive-Drug Resistance 
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 CHAPTER 1: Introduction and literature review 
1.1 TUBERCULOSIS (TB) 
1.1.1 Etiology and history 
Tuberculosis (TB) is a prevalent, and often fatal, infectious disease caused by different strains 
of mycobacterium, mainly Mycobacterium tuberculosis (M.tb).1 M.tb is a small obligate aerobic 
nonmotile bacillum,1 which was identified  by Robert Koch in 1882.2 It is the second highest 
cause of mortality from infectious disease globally after Human Immunodeficiency Virus (HIV) 
infection, and was declared a global public health emergency by the World Health Organization 
(WHO) in 1993.3  
TB predominantly affects the lungs (pulmonary TB), but in some cases, the bacteria  can enter 
the blood stream and spread to other parts of the body (extra pulmonary TB) especially in 
immunocompromised persons like those co-infected with HIV and young children.1 The 
tubercle bacillus replicates slower than most bacteria1 and can adopt a persistent 
nonreplicating state,4 which is unresponsive to treatment. The complex structure and 
composition of its cell wall, which contains peptidoglycans and complex lipids, predominantly 
mycolic acids, contributes to its virulence.1  
Other disease causing strains include Mycobacterium bovis, which is transmitted through 
contaminated milk, or beef, and causes a nonpulmonary form of TB,2 and Mycobacterium 
africanum which  is spread by aerosol transmission and causes a disease similar to that of  
M.tb.1,5 
TB had all but disappeared from public view of developed nations by the late-nineteenth 
centuary,6 largely due to the emergence of effective therapeutic agents and public health 
systems, but it never left the scene in less developed countries.2 This status changed in the mid 













The emergence of multi-drug resistance (MDR) and extensive-drug resistant (XDR) strains of 
M.tb, and the acceleration of disease spread and progression by HIV infection further 
compounded the problem.6 This resistance is either intrinsic, due to the mycobacterium 
structural and functional characteristics that give it the ability to resist the activity of certain 
drugs, or acquired by spontaneous mutations that arise when the mycobacterium is exposed to 
suboptimal drug concentrations.7 The global TB epidemic seems unabated,8 as the pathogen 
uses a number of adaptations to survive in a different host lesions and to hide from immune 
surveillance.1  
TB has a gender and age component as it is more common in men than women,3 except in 
childhood,9 and mostly affects economically productive adults between the ages of 15-59.10 
1.1.2 Epidemiology 
WHO recorded 8.7 million incident cases of TB in 2011.3 Approximately 1 million deaths 
occurred due to TB infection among HIV negative people and an additional 0.4 million deaths 
resulted from HIV associated TB.3 The TB prevalence in 2011 was estimated to be about 12 
million cases worldwide, with 80% TB cases among people infected with HIV in Africa.3 In 
addition there were 3.7% new cases of MDR-TB and 20%  of re-occurrences from previously 
treated TB.3 
The TB burden is highest in Asia and Africa, respectively accounting for 40% and 24% of TB 
cases globally.3 Among the top five countries with the highest incidence of TB, South Africa 
ranks third, with an average of 0.5 million cases in 2011.3 These findings indicate that there are 
shortcomings in the current treatment strategies and the effectiveness of public health systems 
in resource poor countries where the main TB burden lies.8 
An epidemiologic synergy exists between TB and HIV, co-infections represent 13% of the global 
TB incidence, and account for approximately a quarter of HIV/AIDS-associated deaths.3 In this 
synergistic interaction each disease increases the pathogenicity of the other. M.tb causes 
disease at any stage of HIV infection, exacerbates the course of HIV infection by effectively 












less-developed countries.11 In turn, HIV affects the course of tuberculosis in several ways; first it 
promotes progression to active tuberculosis in people with either recently acquired or latent 
tuberculosis infection.11 Secondly it increases the rate of recurrence of tuberculosis following 
treatment completion or cure, mainly due to an increased risk of disease following 
reinfection.12 
Without treatment, TB mortality rates are high. This is further complicated by the emergence of 
resistant strains of M.tb which gives rise to MDR-TB, and XDR-TB, which is almost incurable,13 
accounting for about 5.4% of MDR-TB cases.8 
1.1.3 Transmission and Pathogenesis 
TB is airborne.14 The main mode of transmission is therefore aerosol. When a person with 
active TB coughs or sneezes, tiny particles containing M.tb are expelled into the air. These 
particles, called droplet nuclei, can remain suspended in the air for several hours depending on 
the environment.15 If another person inhales air that contains these droplet nuclei, 
transmission occurs and the droplet nuclei are deposited in the lungs, triggering an immune 
response. 14 
In the lungs, droplet nuclei containing tubercle bacilli travel to the alveoli where they are 
ingested by alveolar macrophages, which destroy or inhibit the majority of them. A small 
number may, however, survive and multiply intracellularly and will be released when the 
macrophages die. Upon release, the bacilli can spread by way of lymphatic channels or through 
the bloodstream to more distant tissues and organs. This systemic dissemination sensitizes the 
immune system for a systemic response. Within two to ten weeks, the immune system 
produces macrophages that surround the tubercle bacilli, forming a hard shell (granuloma) that 
keeps the bacilli contained and under control, a state known as latent TB infection (LTBI).8,14,15  
Although persons with LTBI have M.tb, they do not have the active disease form and are 
therefore unable to spread the infection. 
The unique structure of the M.tb cell wall allows it to lie dormant for many years as a latent 












effectively hiding it from the host’s immune system.1,16 If the immune system cannot keep the 
bacilli under control, the bacilli begin to multiply rapidly leading to TB disease.15 
M.tb requires oxygen to grow, and hypoxia has been shown to induce a non replicative 
metabolic state of bacterial phenotypes, leading to tolerance towards certain drugs.8 Lack of 
potent drug activity on these bacterial phenotypes may be responsible for the prolonged TB 
treatment duration.8 Both the latent asymptomatic state of the disease and the non-replicative 
metabolic state of the bacilli are referred to as the dormant state of the disease.8 It is estimated 
that one-third of the world’s population harbor the latent form of M.tb with a 5% risk (higher in 
immunocompromised persons) of reactivation. The bacilli remain non-pathogenic in healthy 
individuals, and are mostly reactivated in immune compromised persons such as those infected 
with HIV, or those on anti-tumor therapy.8 
1.1.4 Treatment 
TB can be cured,6 with antibiotics being the most effective agents for treatment of actively 
growing M.tb.4 Treatment using combinations of anti-TB drugs developed in the 1940s and 
1950s can dramatically reduce mortality rates.10 Table 1.0 shows some of the drugs currently in 
use.13 
Table 1.0: Drugs currently in use for treatment of tuberculosis
13 




Isoniazid Moxiflaxacin Kanamycin Prothionamide Clofazimine 
Ethambutol Levofloxacin Amikacin Ethionamide Thioacetazone 
Pyrazinamide Ciprofloxacin Streptomycin Cycloserine Linezolide 
Rifampicin Ofloxacin Capreomycin Terizidone Amoxicillin/Clavulonate 
Rifabutin Gatifloxacin  p-amino salicylic 
acid 
Imepenem/Silastatin 












Drugs used in the treatment of TB generally have either bactericidal or sterilizing activity.17,18 
Bactericidal activity is the ability of a drug to kill rapidly replicating M.tb, while sterilizing 
activity is the ability of a drug to kill the slowly replicating or the non replicating forms of 
M.tb17, hence eliminating latent bacilli in persons with LTBI. The sterilizing activity of drugs in 
any given TB regimen determine the duration of treatment as to ensure a reduction of the 
viable bacterial population to levels that will not allow relapses to occur.7,17  
The WHO recommended  standard chemotherapeutic treatment for latent tuberculosis is six to 
nine months of isoniazid (INH).19,20 For active TB treatment, the WHO recommends a treatment 
regimen consisting of two phases, lasting a total of six months, during which four drugs are 
used (Figure 1.0). The initial intensive phase lasts 2 months and consists of treatment with 
rifampicin (RIF), (INH), ethambutol (EMB), and pyrazinamide (PZA). This is followed by a 
continuation phase lasting four months using RIF and INH.20  
 
Figure 1.0: Chemical structures of first line drugs for treatment of active drug-sensitive TB.1 
This regimen is effective and can cure up to 95% of people with non resistant forms of the 












ensure patients compliance.1,4,8,14,21 Patient non-compliance due to the prolonged duration of 
treatment and poor management of chemotherapy, however, has led to the emergence of drug 
resistance, signified by the global appearance of MDR, and XDR-TB strains.1,4   
MDR and XDR TB can either be primary or secondary.15 Primary resistance is caused by person-
to-person transmission of drug-resistant strains of the organisms while secondary resistance 
develops during TB treatment, either because the patient was treated with an inappropriate 
treatment regimen or because of patient non compliance to the prescribed treatment 
regimen.8,15 
MDR-TB is resistant to the two most significant first line antituberculosis drugs INH and RIF.7 
Second line drugs, like fluoroquinolones (Figure 1.1) are used in the treatment of MDR-TB 
although there is no standard regimen14,21 Treatment is individually designed depending on the 
susceptibility of the M.tb strain in question to currently available drugs.14,22 If drug susceptibility 
testing is not available, which is the case in many developing nations, the choice of drugs is 
dependent on the pattern of drug resistance in the local geographical region, drugs the patient 
has been exposed to previously, any patient underlying medical conditions, and the adverse 
effects associated with the drug.21 In the management of MDR-TB the duration of treatment is 
prolonged and varies between 18-24 months and may include a combination of eight to ten 
different drugs, most of which were not originally developed to treat TB.8,21 These drugs are 
often more toxic and less effective than the first line drugs, with low cure rates, ranging from 
50% to 70%.8 
 












XDR-TB is resistant to INH and RIF, as well as any fluoroquinolone and at least one of the 
second line injectable anti-TB drugs amikacin, kanamycin or capreomycin (Figure 1.2).4,14 XDR-
TB is virtually incurable,4 due to very limited treatment options, and it takes much longer to 
treat using third-line anti-TB drugs which are costly and  have more side effects.21 It is 
associated with very high mortality rates, especially for patients co-infected with HIV.8,21  
Recently, the term totally drug-resistant TB (TDR-TB) has been used to describe TB caused by 
M.tb strains that are resistant to all available TB drugs8,14,21 
 













1.1.4.1 Treatment challenges 
Treatment of TB presents many a challenge and, in as much as TB is curable, it takes a minimum 
of six months on a cocktail of various antibiotics to achieve cure. This prolonged duration of 
treatment and the high pill burden has led to poor patient compliance to the recommended 
treatment regimen, which resulted in the emergence of MDR and XDR TB.1,24 The first-line 
treatment regimen has remained essentially unchanged for decades and there have been no 
breakthroughs to decrease either the treatment duration or the pills burden.1,4,8,21,24 
The high pill burden is compounded if the patient is co-infected with HIV, furthermore, 
common antiretroviral drugs are also not compatible with the current TB treatment regimen 
due to shared drug toxicities and drug-drug interactions.1,21 The most significant of these being 
rifampicin-induced cytochrome P450 activation that increases metabolism of protease 
inhibitors, resulting in decreased plasma levels of this class of antiretrovirals, which renders 
them less effective.1,4,25 There has also been reports of incompatibility of the antituberculosis 
agents with drugs used for other chronic diseases such as diabetes.8 
Current anti-TB drugs also have side effects that compound morbidity, leading to poor patient 
compliance, and results in failed treatments or relapses.8,21,24 In addition, the management of 
pediatric TB is difficult since, despite the availability of antibiotics to treat TB, there are no 
suitable drug formulations for children.4 Beyond the medical limitations, the cost of treatment 
is also high in the context of developing nations where the disease is most prevalent.1,4 
To address these challenges, there needs to be efforts to discover new antituberculosis agents 
that will  
i. shorten the duration of treatment 
ii. reduce the pill burden and lower dosing frequency 
iii. be effective in treating latent, MDR and XDR TB 
iv. be suitably formulated to manage pediatric TB 












vi. be effectively co-administered with other drugs for chronic illnesses especially HIV. 
1,4,8,19 
Although there is an existing pipeline of drugs under development that will bring new 
antituberculosis agents into clinical use in the near future,1,26,27 it is still not sufficient to address 
the alarming rate at which the current drugs are becoming ineffective due to resistance, which 




























1.2.1. Etiology and history 
Malaria is a parasitic infectious disease caused by parasites of the genus Plasmodium.28 The 
name malaria originates from the Italian terms “mal” or bad and “aria” or air. It means foul or 
bad air as people initially noted that malaria was common in areas surrounding marshes and 
swamps, and  pegged the disease on rot and decay that passed out through the foul air.29–31 
Malaria is an ancient disease, but it is only in 1880 that Alphonse Laveran, a French military 
physician, discovered the single-celled Plasmodium parasite as the real cause of malaria.29 Years 
later, between 1889 and 1900, Italian researchers discovered that the Anopheles mosquitoes 
are responsible for transmitting the disease. 29,31,32 
There are more than 100 different species of plasmodium29 but only five have been identified 
as being able to cause malaria in humans, these are Plasmodium falciparum, vivax, malariae, 
ovale and knowlesi.30,33 Plasmodium knowlesi is predominantly a monkey species but can cause 
severe human infections with cases being reported in South-East Asia.3435  Plasmodium 
falciparum is the most virulent, causing the most deaths due to malaria.29,36 In Africa, children 
under the age of 5 years and pregnant women are the most at risk.28,33 Plasmodium vivax is not 
as virulent as P. falciparum, but is the most geographically widespread of all the species30 and is 
associated with relapses occurring up to three years with a debilitating chronic disease. 
Plasmodium malariae can persist asymptomatically in blood for a long time, while Plasmodium 
ovale is rare and also associated with relapses.29,30,33,35 
In the mid 1950s and 1960s, the WHO started a worldwide campaign to eradicate malaria by 
controlling the transmitting vector and treating of infected people.29,37 This was successful for a 
while with malaria being completely eradicated in some places.32 However, this was short lived 
as some strains of Anopheles mosquitoes developed resistance to the insecticides used for their 
control, and the Plasmodium parasites became resistant to chloroquine, the mainstay of 












Since then various antimalarial agents have been developed and used for the treatment of the 
disease.36 However, the high cost of the drugs, severe side effects, toxicities, and the rapid 
spread of resistance to these drugs has seriously compromised their efficacy and use.28 Of 
significance is the recent evidence of the possible emergence of resistance to the current first-
line artemisinin-combination therapy (ACTs), in South-East Asia, which threatens the current 
clinical efficacy of these compounds and create the need for continuous search for novel and 
structurally diverse compounds with potent antiplasmodial activity.30,33,35,38–40 
1.2.2 Epidemiology 
Malaria has a worldwide distribution, being found in tropical areas, throughout sub-Saharan 
Africa and to a lesser extent in South Africa, South-East Asia, the Pacific islands, India and 
Central and South America.30,36 
There were an estimated 219 million cases of malaria (range154–289 million) and 660 000 
deaths from malaria (range 610 000–971000) in 2010.30 Globally, an estimated 3.3 billion 
people were at risk of malaria in 2011, with populations living in sub-Saharan Africa at highest 
risk.30 Approximately 80% of malaria cases and 90% of  the deaths are estimated to occur in 
Africa.30 Out of 43 countries in Africa with ongoing malaria transmission, only 8 countries have 
achieved  a greater than 75% reduction in malaria case incidence or malaria admission rates.30 
Population migration due to business, commerce, and tourism has resulted in more people 
from non-endemic countries being exposed to malaria.36 
Since malaria is associated with poverty, mortality rates are highest in developing nations, 
especially in countries where a higher proportion of the population is living in poverty. The 
prevalence of malaria infections in children less than 5 years of age is also highest in poorer 
populations and rural areas. 28,30,41,42 Malaria is prevalent in tropical and subtropical regions 















1.2.3 Transmission and Pathogenesis 
Human malaria occurs by transmission of Plasmodium sporozoites via a bite from an infected 
anopheles mosquito43,44 (Figure 1.3). The sporozoites travel from the salivary glands of the 
mosquito through the bloodstream of the host to the liver, where they invade hepatocytes.43,44 
These cells divide repeatedly to form mature tissue schizonts, each containing thousands of 
daughter merozoites.31,43 This is called the exoerythrocytic stage of infection and is 
asymptomatic31,35,44 
 
Figure 1.3:  Malaria parasite life cycle-adapted from the CDC public health image library
45
 
The liver schizonts rupture after one to two weeks in P. falciparum- longer in other species-and 
release merozoites into the bloodstream where they invade erythrocytes.29,35 This is known as 
the erythrocytic stage of the infection.44 In P. vivax and P. ovale infection, some parasites 
remain dormant in the liver as hypnozoites and can cause late relapse by reactivating after 
many months.36,43 P. malariae doesn’t form hypnozoites but can cause very late relapse due to 












Within the erythrocytes merozoites undergo a cycle of asexual reproduction, forming schizonts 
filled with more merozoites. When these schizont mature, the cell ruptures and merozoites 
together with the parasite’s waste and cell debris are released into the blood stream, and are 
responsible for the clinical symptoms of malaria, such as high and periodic fevers, nausea and 
vomiting, chills, abdominal and back pain, headache, diarrhea, and anaemia.29,43 The newly 
released merozoites invade other erythrocytes, and this process is repeated almost indefinitely 
and continues until it is brought under control, either by treatment or the body’s immune 
system.28,29 
The merozoites mature successively from ring forms to trophozoites to mature red cell 
schizonts, the asexual forms of the parasite, over 24 hours for P. knowlesi, 48 hours for P. vivax, 
P. ovale, and P. falciparum and 72 hours for P. malariae.36,41,43 Within the erythrocytes the 
parasites digest hemoglobin.29 The breakdown of hemoglobin in the parasite food vacuole leads 
to accumulation of toxic breakdown products which the parasite gets rid of by formation of  
hemozoin, a polarizable crystal as a detoxification mechanism.43 A few merozoites differentiate 
into male or female gametocytes, the sexual form of the parasite, which cause no symptoms 
but can circulate in the bloodstream until they are ingested by a blood-feeding Anopheles 
mosquito.29 
In the mosquito sporogony begins when the gametocytes mature into male and female 
gametes, which then can undergo fertilization to form a motile zygote (ookinete) inside the 
lumen of the mosquito gut.31,36,43 The ookinete then penetrates the mosquito gut wall and 
develops into an oocyst which contains sporozoites that are released upon its rupture and 
migrate to the salivary glands ready for injection into a new host. The cycle is then 
repeated.28,29,31,35,41,43,46 
1.2.4 Treatment 
Malaria can be effectively controlled and treated.30 Management of malaria requires a 
combination of preventive measures, vector control and active disease treatment. The 












friendly insecticides have positively contributed to the reduction of the disease burden.28,30,32,34 
The prompt treatment of malaria with effective antimalarial drugs to completely cure the 
disease, prevent death, and get rid of the human reservoir of malaria infection and curbing its 
transmission is the objective of malaria chemotherapy.34  
There are several broad classes of antimalarial drugs in clinical use based on their mode of 
action.28,36,43 Quinolines and related compounds are thought to block parasite heme 
detoxification by preventing the formation of hemozoin.47,48 This class of compounds includes 
some of the oldest known antimalarial agents such as quinine, chloroquine, amodiaquine, 
mefloquine, piperaquine and some newer agents like lumefantrine36,43,44 (Figure 1.4). 
 
Figure 1.4:  Chemical structures of quinolines and other related compounds
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Antifolates interfere with folate metabolism hence inhibiting nucleic acid synthesis, a pathway 
that is essential for malaria parasite survival.47 This class includes sulfadoxine and 













Figure 1.5:  Chemical structures of antifolate antimalarial agents
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Artemisinine derivatives are the most recent class of antimalarial agents to enter the market 
and though their mode of action is not well understood, they are thought to interfere with 
heme detoxification via radical formation and/or heme alkylation although these mechanisms 
are not well understood.47 The artemisinins include artesunate, artemether, and 
Dihydroartemisinin36 (Figure 1.6).  
 
Figure 1.6:  Chemical structures of artemisinin derivatives
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Atovaquone, a hydroxynaphthoquinone antiparasitic agent, interferes with cytochrome 
electron transport, and is combined with proguanil (Figure 1.7) for the treatment of malaria for 
synergistic effect.34,47 Proguanil is a biguanide that is metabolized in the body via cytochrome 
P450 to the active metabolite, cycloguanil, which inhibits plasmodial dihydrofolate reductase. 

















Antibiotics used in the treatment of malaria mainly act by inhibiting protein synthesis. They 
include the tetracycline’s such as tetracycline and lincosamides such as clindamycin (Figure 
1.8).28,34–37,43,49,50 
 
Figure 1.8:  Chemical structures of antibiotics used in treatment of malaria
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To minimize the  development of resistance to the drugs and cross resistance between 
structurally similar drugs,  combinations of drugs with different mechanisms of action has been 
adopted in malaria chemotherapy.28,30,33,48,51,52 
The guidelines provided by the WHO for the treatment of malaria are based on the 
classification of the disease as either uncomplicated or complicated. Uncomplicated malaria is 
symptomatic malaria without any signs or evidence of severity and/or vital organ dysfunction. 
The signs and symptoms are normally nonspecific and hence, uncomplicated malaria is clinically 
suspected mainly on the basis of fever or a history of fever. Complicated malaria presents with 
one or more of the features of vital organ dysfunction such as prostration, altered 
consciousness, respiratory distress, multiple generalized convulsions, severe anemia, 












Artemisinin combination therapies (ACTs) are recommended by the WHO as standard 
treatment for uncomplicated malaria.28,34,51 The artemisinin derivative component of the 
combination must be given for at least three days for an optimum effect to be achieved.34 
Recommended ACTs include artemether plus lumefantrine, artesunate plus amodiaquine, 
artesunate plus mefloquine, artesunate plus sulfadoxine-pyrimethamine, and dihydrortemisinin 
plus piperaquine.30,34 
For complicated malaria both in adults and children, the WHO recommends parenteral 
artesunate 2.4 mg/kg bodyweight given intravenously (IV) or intramuscularly (IM) on admission, 
at 12 hours, 24 hours, and once daily thereafter. Artemether or quinine are an acceptable 
alternative if parenteral artesunate is not available, and they should be administered as 
artemether 3.2 mg/kg IM given on admission then 1.6 mg/kg per day thereafter; or quinine 20 
mg salt/kg  on admission as an IV infusion or divided IM injections, then 10 mg/kg every 8 hours 
thereafter. The parenteral antimalarials should be administered for a minimum of 24 hours 
once started, irrespective of the patient’s ability to tolerate oral medication earlier. Thereafter, 
once the patient can tolerate oral medication, a complete treatment with any of the ACTs 
should be administered.30,34  
1.2.4.1 Treatment challenges 
The rapid development of resistance to known antimalarials compared to the rate at which new 
agents are coming into the market is the biggest challenge in malaria drug discovery.28 
Currently, resistance to ACTs has already been documented in South-East Asia, yet there is no 
ready alternative to these drugs.34,50 Multi-drug and cross-drug resistance, especially with 
aminoquinolines, also highlights the need for new agents with novel mechanisms of action.48 
Access to antimalarial drugs is limited because of their cost and problems with distribution,  
especially in developing nations where the malaria burden is great.51 Although pharmaceutical 
companies have provided subsidies in recent years, this may not be sustainable in the long run 












Patient compliance to treatment is  hampered due to severe side effects and  toxicities of most 
antimalarial drugs such as anorexia and loss of balance with mefloquine, agranulocytosis with 
amodiaquine, and chinconism with quinine.34,39 Compliance is also decreased due to the 
inability of patients, especially in rural settings, to follow treatment correctly and the 
unavailability of suitable formulations for children.42 
To address these challenges there needs to be an effort to discover new antimalarial agents 
that are, 
i.  safe and well tolerated-especially by children and pregnant women 
ii. orally bioavailable 
iii. effective against drug resistant strains of Plasmodium 
iv. acting via new mechanisms to prevent rapid development of resistance and/or cross-
resistance 
v. cheap and affordable in resource poor settings 
vi. able to achieve cure within a short duration of time 




















1.3 DRUG DISCOVERY STRATEGIES 
1.3.1 Drug discovery through screening in treatment of TB and Malaria 
There are a number of strategies that have been employed to fast track TB and malaria drug 
discovery efforts. One such strategy is the screening of pharmaceutical compound libraries to 
identify novel compounds with antimycobacterial or antiplasmodial activity (hits). This is known 
as a species specific platform for drug discovery. It is normally followed by synthesis, 
modification or derivatization of the identified hits to improve their activity and decrease any 
associated toxicities. It is quite common for drug discovery efforts to start from the 
identification of hits from high throughput screens.8,16,19,52 
Recently this strategy has given rise to one of the most promising antituberculosis agents to 
enter clinical trials. Diarylquinolines were discovered to have antitubercular activity through 
whole cell screening of a library of compounds for potential anti-TB activity. Derivatization then 
led to the discovery of TMC207, 1,4,8,13,14,18 (Figure 1.9), the most potent compound of the 
series. 
 
Figure 1.9: Chemical structure of TMC207.
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TMC207 has recently been approved as bedaquiline® by the US Food and Drug administration 
(FDA) through its regulatory path for accelerated review of limited efficacy data, as part of a 
combination regimen for management of MDR-TB where no other treatment options are 
available.21 The benzothiazine BTZ043, which is currently in pre-clinical development, was also 
discovered through such screens.8,21 
In malaria drug discovery high-throughput screening (HTS) efficacy models have been widely 
used at early stages of drug discovery and development.48 This method recently resulted in the 












of a BioFocus DPI Soft Focus kinase library. Further work on these compounds led to the 
identification of the compound MMV390048 33,39,53 (Figure 2.0) which is currently in preclinical 
studies. 
 
Figure 2.0: Chemical structure of MMV390048
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1.3.2 Drug repurposing and repositioning in the treatment of TB and malaria 
A more common approach to identify TB and malaria drugs is by direct repurposing, or 
repositioning of existing antimicrobials and other drugs for non infectious indications. Drug 
repurposing is the investigation of new uses for existing drugs, whether in clinical use or not 
without any structural modification of the drug. Drug repositioning differs from repurposing in 
that the drug in question undergoes structural modifications to improve the desired 
activity.25,26,52 
Drug repurposing and repositioning has been succefully applied in TB drug discovery in the past,  
and has become a useful tool in finding new drugs with decreased costs and duration of 
research.4,25,26 In fact, some current drugs that are central in TB treatment were initially 
developed for other indications and repurposed or repositioned for management of TB.8,21,25–27 
The repurposing of fluoroquinolones is a classic example. Fluoroquinolones were originally 
developed as broad spectrum antibiotics for treatment of severe bacterial infections. However, 
they are now the drugs of choice in the management of MDR-TB. Structural modifications of 
the original quinolones led to new compounds with improved activity. Two of these 
compounds, gatifloxacin and moxifloxacin (Figure 2.1), are said to have the potential to 













Figure 2.1: Chemical structures of fluoroquinolones with potential of shortening treatment duration.
21 
The repositioning of the oxazolidinone linezolid (Figure 2.2), originally in clinical use for 
treatment of infections caused by methicillin-, vancomycin- and penicillin-resistant bacterial 
strains, is another success story. It was found to be active against M.tb. However, prolonged 
use was associated with toxicities such as anemia and peripheral neuropathies. Structural 
modifications of linezolid gave rise to sutezolid (PNU100480) which is  believed to be more 
potent and safer, and is currently in phase II clinical trials.4,8,13,14,21,25,26 
 
Figure 2.2: Chemical structures of linezolid and its active analogue PNU100480
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In malaria chemotherapy, repositioning and repurposing is well exemplified by the antibiotics 
currently in use both for malaria treatment and prophylaxis. Doxycycline (Figure 2.3) is the 
most widely used of the tetracycline antibiotics in the management of malaria. It has become 
the mainstay in malaria prophylaxis in cases where mefloquine is contra-indicated or in areas 














Figure 2.3: Chemical structure of doxycycline, an antibiotic used in malaria prophylaxis 
25
 
The antifolate class of antimalarials is another example of repurposing in malaria 
chemotherapy. Originally developed as antibacterial agents, these drugs have been repurposed 
in malaria treatment. They are successfully used in drug combination due to their synergistic 
effects although wide spread resistance has been reported.25,43,44,52 
In the work presented in this dissertation two compounds of interest (Figure 2.4) were 
identified from different HTS campaigns conducted by the Tuberculosis Antimicrobial 
Acquisition and Coordinating Facility (TAACF), a programme established to allow researchers 
access to high quality screening services.54 One of these compounds is metergoline, a drug in 
clinical use for non infectious conditions while the other belongs to the thiazole class of 
compounds which have diverse pharmacological application.  
 
Figure 2.4: Chemical structures of metergoline and the thiazole scaffold of interest 
The HTS demonstrated that metergoline and the 2-amino-4-heteroaryl thiazole scaffold (Figure 
2.4) with an aryl or aryl alkyl substituent on the amino group at the position 2 exhibited 
antitubercular activity. It was therefore envisioned that through medicinal chemistry these 
compounds could be derivatized in an attempt to come up with analogues with improved 
antitubercular activity. The decision to test for antiplasmodial activity was based on the fact 













CHAPTER 2: Design, Synthesis and Pharmacological evaluation of Thiazole Derivatives 
2.1 Introduction  
This chapter describes the design, synthesis and characterization of some novel thiazole 
derivatives, derived from the 2-amino-4-heteroaryl thiazole scaffold (Figure 2.5). Structure-
activity relationship studies were conducted to investigate the effect on activity of different 
structural motifs on the scaffold. Standard organic synthetic routes were used in the synthesis. 
All synthesized derivatives were evaluated for in vitro antimycobacterial and antiplasmodial 
activity as well as cytotoxicity, and also profiled for their physicochemical and Absorption, 
Distribution, Metabolism and Excretion (ADME) properties. 
 




Thiazole (Figure 2.6) is a heterocyclic compound containing both nitrogen and a sulfur atom as 
part of the aromatic five-membered ring. It’s aromaticity is due to the delocalization of a lone 
pair of electrons from the sulfur atom giving the required 6 π electrons to satisfy Huckel’s 
rule.55  
 
Figure 2.6: Chemical structure of the thiazole ring
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Thiazoles are important for their wide range of pharmaceutical and biological properties,57 and 
thiazole derivatives are known to exhibit an array of biological activities such as anticonvulsant, 
antimicrobial, anti-inflammatory, anticancer, antidiabetic, anti-Alzheimer’s, antihypertensive, 
antioxidant, anti-HIV,58 and are found  in a number of clinically used drugs such as Sulfathiazole 














Figure 2.7: chemical structures of thiazole containing drugs in clinical use 
  2.2.1 Previous Studies on the Antimycobacterial Activity of Thiazoles 
In a recent study conducted in 2011, K.K.Roy et al. demonstrated the antimycobacterial activity 
of some substituted 4-arylthiazol-2-amino derivatives. They synthesized and evaluated a series 
of analogues for antimycobacterial activity, and compounds 1 and 2 (Figure 2.8) both with an 
MIC99 of 6.25 µM effectively inhibited the growth of replicating M.tb.
24 
 
Figure 2.8: Chemical structures of 4-arylthiazol-2-amino analogues with antimycobacterial activity24                    
In a different study G. Turan-zitouni et al elicited antitubercular activity in compound 3 (Figure 
2.9) which is an N-pyridyl-N’-thiazolylhydrazine derivative. The compound had an IC90 of 
6.78µg/ml  and further studies on it are still in progress.19 
 













2.2.2 Previous Studies on the Antiplasmodial Activity of Thiazoles 
A. Cohen et al. explored the antiplasmodial potential of new naphtho-[2,1-d] thiazole analogues 
and reported two hits, compounds 4 and 5 (Figure 3.0), with IC50 values of 4.8 and 2.7 µM in 
vitro activity against chloroquine and multi-drug resistant P. falciparum strain.40 
 
Figure 3.0: Chemical structures of naphtho-[2, 1-d] thiazole analogues with antiplasmodial activity40 
D. Cabrera et al. demonstrated the antimalarial activity of an aminomethylthiazole pyrazole 
carboxamide 6 (Figure 3.1). The compound had good in vitro antiplasmodial activity with an IC50 
of 0.08µM against the K1 (chloroquine and multi-drug resistant strain) and 0.07µM against the 
NF54 (chloroquine sensitive) P.falciparum strain and demonstrated in vivo efficacy in the 
P.berghei mouse model at a dose of  4 X 50mg/kg when administered orally.38 
 
Figure 3.1: Chemical structure of an aminomethylthiazole pyrazole carboxamide with antimalarial activity38 
2.3 Rationale             
Substitutions on the thiazole ring have proven highly effective in improving potency as in the 
studies above. As mentioned in Chapter 1, a HTS conducted in 2009 by TAACF, demonstrated 
that the 2-amino-4-heteroaryl thiazole scaffold (Figure 2.5) possesses antimycobacterial 
activity. Out of 100,997compounds from the Chembridge library, and 1120 compounds from 












single dose assay at 10µg/ml, 15 of these 18 compounds showed > 90% inhibition of growth. 
These 15 hits were screened in a dose-response assay from 50µg/ml to 0.098µg/ml and 13 of 
them had sub µg/ml TB IC90 values. Most of these compounds had a substituted phenyl or 
pyridyl group at the 2-amino position of the thiazole ring, and all active compounds had the 2-
pyridyl group at position 4 of the thiazole ring. Some compounds which were 3-pyridyl and 4-
pyridyl analogues (at position 4 of the thiazole ring) of the active compounds which were 
present in the library were found to be inactive, indicating optimum activity was with the 2-
pyridyl group at this position.54  
There are no Structure-Activity-Relationship (SAR) studies reported on this class of compounds 
to the best of our knowledge, therefore, in this study the SAR of the 2-amino-4-heteroaryl 
thiazole scaffold was conducted with the aim of validating the essentiality of each component 
attached to the scaffold for activity, expanding the SAR at the 2-amino position and 
investigating the findings from the HTS that the 2-pyridyl group at position 4 of the thiazole ring 
was optimum for activity (Figure 3.2)      
 
Figure 3.2: Investigated SAR series of the 2-amino-4-aryl thiazole scaffold. 
The scaffold was investigated in the 3 different series described below: 
i. Series 1 (SAR 1) - effect on activity of a substituted phenyl group at the 2-amino position 
ii. Series 2 (SAR 2) - essentiality of the heteroaryl group at  position 4 of the thiazole 
moiety 
iii. Series 3 (SAR 3) - importance of the linker between the thiazole moiety and the 













Synthesis and SAR evaluation of 2-amino-4-heteroaryl thiazole derivatives as antimycobacterial 
and antiplasmodial agents. 
2.4.1 Research Question 
Is it possible to identify 2-amino-4-heteroaryl thiazole derivatives with potent 
antimycobacterial and/ or antiplasmodial activity and favorable drug metabolism and 
pharmacokinetic properties? 
2.4.2 Specific Aims: 
1. Synthesis of target compounds 
2. Characterization of the target compounds using analytical and spectroscopic techniques 
3. Conducting in vitro solubility profiling of synthesized compounds 
4. Evaluating synthesized compounds for pharmacological (antimycobacterial and 
antiplasmodial) activity. 
5. Performing in vitro microsomal metabolic stability profiling of the most potent 





















2.5 Series 1-Introduction, Synthesis and Characterization 
2.5.1 Introduction 
In determining the derivatives to be synthesized, it was envisioned that it would be 
advantageous if a rational approach could be followed in deciding which substituted analogues 
to make. The QSAR (quantitative structure-activity relationship) approach was used. QSAR tries 
to identify and quantify the physicochemical properties of a molecule and determine whether 
any of these properties has an effect on the biological activity. It allows some level of prediction 
by quantifying a linear relationship between a physicochemical property of a drug and its 
biological activity.59   
 
Figure 3.3: The Craig plot 
Thus substituents on the phenyl ring, in this case, were selected by use of a Craig plot. This is a 
plot of π (pi) (substituent hydrophobicity constant) on the x axis and σ (sigma) (Hammett 
substitution constant,) of substituents on the y axis (Figure 3.3).  
Pi is a measure of the hydrophobic character of a substituent and indicates how easily it crosses 
cell membranes, and interacts with receptors. Sigma is a measure of the electronic effects of a 












can pass through cell membranes or how strongly it can bind to receptors. Changing 
substituents on a molecule may therefore have a significant effect on its hydrophobic and 
electronic character and hence its biological activity .59 
Here derivatives of 2-amino-4-heteroaryl thiazoles with a phenyl group having substituents 
selected from the Craig plot were synthesized and profiled for physicochemical properties and 
pharmacological activity. 
2.5.2 Synthesis of 4-R-N-[4-(2-pyridinyl)-2-thiazolyl]–benzamides 
The desired targets were synthesized in a 3-step reaction sequence (Scheme 1.0) starting from 
commercially available 2-acetylpyridine, which was stirred in a mixture of 48% HBr and Br2 for 1 
hour at 65oC, and then for a further 1 hour at room temperature to yield FM001 as an orange 
solid in moderate yields. 
 
Scheme 1.0: Reagents and conditions; (i) HBr (48%), Br2, 65
o
C  →RT, 2hr; (ii) Thiourea, EtOH, RT, 1hr; 
(iii)Appropriate carboxylic acid, EDCI, HOBt, DCM, RT, 24 hr. 
The first step is an α-bromination reaction via enol formation to yield the α-bromoketone 
FM001. -Haloketones are useful reagents in heterocyclic synthesis as they are highly reactive 
towards incoming nucleophiles. The reactivity of α-haloketones is due to the inductive effect of 
the carbonyl group which enhances the polarity of the carbon-halogen bond by increasing the 
electron deficiency at the α-carbon atom. In addition, the more polar the C-X bond, the faster 
the reaction with nucleophiles. Thus the formation of  FM001  is necessary to enhance 
reactivity during thiazole ring formation in  the second step.60 The HBr solvent acts to protonate 
the ketone, which promotes the reaction in two ways.  First it increases the electrophilicity of 












and picks up a beta proton, giving the enol tautomer, which is nuclephilic enough to attack Br2, 
forming FM001 as an HBr salt. 
 The second step of the reaction involves the formation of a thiazole ring when FM001 is stirred 
at room temperature with thiourea in ethanol for 1 hour. The reaction proceeds via a Hantzsch 
synthesis61 to yield the primary amine FM002 as a pink powder in moderate yields. 
FM002 is the key intermediate in this series, and it is formed via the condensation of the α-
bromoketone FM001 with thiourea (Figure 3.4).  
 
Figure 3.4: Proposed mechanism of formation of the 4-(pyridin-2-yl) thiazol-2-amine FM002. 
The reaction is driven by the nucleophilicity of the amine groups attached to the sulfur atom in 
thiourea which causes it to attack the bromine bearing carbon of the α-bromoketone via an SN2 
mechanism thus displacing bromine and forming an S-C bond. This is followed by the 
deprotonation of the imminium ion intermediate to form an imine which enhances the 
nucleophilicity of the nitrogen, with generation of HBr. HBr enhances the polarization of the 
carbonyl by protonating it to form an oxonium  ion. The electrophilic carbonyl carbon is then 












then deprotonates the iminium and regenerates HBr. As the product still exists as an HBr salt at 
this point, sodium bicarbonate is used to neutralize the HBr to generate the final product as a 
free base.  
The final step of the reaction is an EDCI (1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide)- 
mediated coupling of FM002 with a range of different appropriately substituted carboxylic 
acids. This was accomplished by adding the EDCI in small portions to a solution of the 
appropriate carboxylic acid and HOBt in dry DCM solvent and allowing this reaction mixture to 
stir for 10 minutes, followed by addition of the primary amine FM002 as a solution in dry DCM. 
The reaction mixture was then left to stir for 24 hours at room temperature and the target 
benzamides isolated as solids in varying yields (Table 1.1).  
EDCI is a coupling reagent used to activate carboxylic acid during amide synthesis by replacing 
the hydroxyl group of the carboxylic acid with a bulkier and better leaving group hence 
enhancing the acid reactivity. The initial step in the activation process is the addition of the 
carboxyl group to the carbodiimide to form an O-acylisourea intermediate which is then 













 Figure 3.5: Proposed mechanism for the EDCI mediated coupling to form on amide bond 
The EDCI and the carboxylic acid are left to react for ten minutes before the amine is added, in 
order to give time for this activated intermediate to form. The formation of the O-acylisourea is 
very fast and it then reacts with the incoming amine to form an amide bond. The O-acylisourea 
is very reactive and may undergo rearrangement via an intermolecular acyl transfer to form the 
more stable and unreative N-acylurea. If this occurs, it would lead to low reaction yields owing 
to decreased amounts of the O-acylisourea that the amine can react with to give the desired 
product. The addition of HOBt (1-hydroxybenzotriazole) is used to suppress the formation of 
this unreactive species, hence improving the yields. Yields may be further decreased when 
equilibrium is reached between the carboxylic acid, and the O-acylisourea. At equilibrium, 
formation of the symmetrical anhydride occurs because the reaction of the O-acylisourea with 












Table 1.1: Isolated yields, molecular ion peaks and melting points of the 4-(pyridine-2-yl)-2-thiazol amide 
derivatives 
                                                                     
Compound code   R % YIELD 
[M]+ Melting Point 
( oC ) Expected Found 
RIZ 003 
       
41 360.97       360.98 182-184 
RIZ 004 
      
42 406.96        406.95 200-202 
RIZ 006 
     
32 359.04        358.93 275-277 
RIZ 007 
     
38 323.07        323.00 162-163 
RIZ 008 
      
44 306.06        305.98 220-221 
RIZ 009 
      
18 326.05        325.95 238-239 
RIZ 010 
     
28 349.05        349.04 225-227 
RIZ 011 
     
27 365.04        365.04 176-177 
RIZ 012 
     
29 309.09        309.07 168-170 
RIZ 013 
  
52 337.12        337.03      93-95 
RIZ 015 
    












Compound code   R % YIELD 
[M]+ Melting Point 
( oC ) Expected Found 
RIZ 017 
    
26 315.02        315.02 195-197 
RIZ 018 
      
21 299.05        299.03 179-181 
RIZ 020       64 281.06        281.04 135-137 
RIZ O21 
      
56 360.97        360.91 178-180 
RIZ 022 
     
70 360.97        360.87 176-178 
RIZ 023 
       
62 282.06        281.94 148-150 
RIZ 024 
       
25 282.06        282.04 232-234 
RIZ 025 
      
22 282.06        282.01 215-217 
RIZ 038 
      
17 288.01        287.90 203-205 
RIZ 039 
      
12 271.05        270.77 229-231 
RIZ 042 
    


















Spectroscopic Analysis of key intermediates and the final target compounds. 
As the amides are derivatives of the same scaffold, many aspects of their NMR spectra are 
similar; therefore only one representative compound is described here.  Most compounds in 
this series contained the thiazole ring, the amide linker, a phenyl ring substituted at para 
position and a 2-pyridine ring.  These components give rise to characteristic peaks that allow for 
confirmation of the compounds being derivative of the 2-amino-N-(2-pyridinyl) thiazole 
scaffold. 
The 1H NMR spectrum of FM001 agrees with that reported in literature.64  The mass spectra 
gave the expected molecular ion peak with an M/Z ratio of 198.96 at 39.2% of the baseline, 
thus confirming the compound synthesized was the hydrobromide salt form. 
The 1H NMR spectrum for FM002 shows the appearance of the NH2 protons at 7.08 ppm as a 
broad singlet integrating for 2 H (Figure 3.6). Replacement of the keto group by a thiazole ring 
affects the relative shifts of the pyridyl protons.  The thiazole being electron donating provides 
a shielding effect which results in a slight upfield proton shift relative to FM001. A sharp singlet 
at 4.97 ppm, corresponding to the –CH2 in FM001 disappears and there appears a new singlet 
in the aromatic region corresponding to H5 of the thiazole ring. The 13C NMR spectrum 
indicates that all the expected carbons are present. The mass spectra gave the expected 
molecular ion peak with an M/Z ratio of 176.92 at 100% of the baseline, thus confirming the 
compound synthesized was the free primary amine. The melting point of the salt was found to 
be 174-176C, which falls within range of the reported literature melting point  of 173-174C.65 
The 1H NMR spectrum of RIZ015 shows the disappearance of the –NH2 protons observed in 
FM002 and the appearance of the –NH proton  of the amide group appearing downfield at a 
high chemical shift value of 12.60 ppm, indicating the successful  coupling between the amine 















H NMR of FM002 in DMSO-d6 at 400 MHZ (top) 
1
H NMR of RIZ015 in DMSO-d6 at 400 MHZ (bottom) 
The pyridyl protons remained in the same aromatic region with the single proton of the thiazole 
ring H5 appearing at 7.92-7.85 ppm with H3 as a multiplet. A singlet appearing at 2.56 ppm is 
representative of H8, the methyl protons of the methylthio group. The 13C NMR spectrum 
indicates that all the expected carbons are present. The most upfield carbon in the spectrum is 
the –CH3 group at 14.50 ppm, due to its attachment to the sulfur, while the most downfield 
carbon at 164.74 ppm corresponds to the carbonyl carbon. The mass spectra gave the expected 














2.6 Series 2-Introduction, Synthesis and Characterization 
2.6.1 Introduction  
As mentioned earlier all active compounds from the HTS had a 2-pyridyl group at position 4 of 
the thiazole ring. Isomers of some of the active compounds with 3-pyridyl and 4-pyridyl groups 
at this position were present in the library and were found to be inactive, indicating optimum 
activity was with the 2-pyridyl group.54 To investigate the findings from the HTS that the 2-
pyridyl group at position 4 of the thiazole ring was optimum for activity, two analogues of the 
compound RIZ 003 were synthesized where the 2-pyridyl group was replaced with a 3 and 4-
pyridyl ring respectively. RIZ 003 was selected as it had shown the best antimycobacterial 
activity in the preliminary screen. 
2.6.2. Synthesis of 3-pyridyl and 4-pyridyl analogues of RIZ 003 
 
The compounds were synthesized in a 3 step reaction similar to the ones described for series 1 
above in 2.5.2 but starting from commercially available 3-acetylpyridine and 4-acetylpyridine 
respectively (Scheme 1.1).  
 
Scheme 1.1:  Reagents and conditions; (i) HBr (48%), Br2, 65
o
C→RT, 2hr; (ii) EtOH, RT, 1hr; (iii) EDCI, HOBt, DCM, 
RT, 24 hr. 
 













Table 1.2: Isolated yields, molecular ion peaks and melting points of the 3-pyridyl and 4-pyridyl analogues of 
RIZ003 
 
            Compound code   R % YIELD [M]+ Melting Point 
(oC) Expected Found 
RIZ 034 
      
20 360.97        360.87 233-235 
RIZ 035 
      
23 360.97        360.86 251-253 
 
Spectroscopic Analysis N-4-bromo-N-[4-(3-pyridinyl)-2-thiazolyl]-benzamide RIZ 034 
The 1H NMR spectrum shows the downfield appearance of the –NH proton of the amide group 




H NMR of RIZ034 in DMSO-d6 at 400 MHZ 
The pyridyl protons H1-H4 remained in the same aromatic region, but with extensive coupling, 












changed. The singlet appearing at 7.86 ppm is representative of the H5 of the thiazole ring. The 
13C NMR spectrum indicates that all the expected carbons are present within a similar high 
frequency range as expected since they are all –CH or tertiary carbons. The most downfield 
carbon is at 165.02 ppm and corresponds to the carbonyl carbon. There were also two sets of 
equivalent carbons of the phenyl ring. The mass spectra gave the expected molecular ion peak 
with an M/Z ratio of 360.87 at 38.0% of the baseline. 
2.7 Series 3-Introduction, Synthesis and Characterization 
2.7.1 Introduction 
This series sought to investigate the effect of the linker between the thiazole moiety and the 
substituted aryl group via position 2 of the thiazole moiety. Here analogues of RIZ 020 were 
synthesized with different bridges linking the 2-amino-4-(2-pyridyl) scaffold and the phenyl ring. 
RIZ 020 was selected as the materials for synthesis were readily available. 
2.7.2 Synthesis of RIZ 020 analogues with various linkers 
 
2.7.2.1. Synthesis of N-phenyl-[4-(2-pyridinyl) thiazole-2-amine, RIZ 020B 
This compound was prepared by refluxing commercially available phenylthiourea and FM001 in 
ethanol for 1 hour, (Scheme 1.2), and then cooling the mixture and adjusting its pH to 
approximately 8 using NaHCO3, and then stirring for a further 2 hours at 20
oC. RIZ 020B was 
isolated as a brown solid in 59% yield. 
 
















The reaction occurs in the same manner as described in step two of 2.5.2, but in this case an N-
phenyl substituted thiourea was used. 
Spectroscopic Analysis N-phenyl-[4-(2-pyridinyl) thiazole-2-amine, RIZ 020B 
The 1H NMR spectrum is as that reported in literature (Figure 3.8),64 and shows the downfield 
appearance of the –NH proton of the amine at 10.27 ppm, slightly lower than the one observed 




H NMR of RIZ020B in DMSO-d6 at 400 MHZ 
The pyridyl protons remained in the same aromatic region, some with extensive coupling hence 
appearing as multiplets. The singlet representing H5 appears at 7.53 ppm. The phenyl ring being 
unsubstituted gives 3 signals as expected. The 13C NMR spectrum indicates that all the expected 
carbons are present within a similar high frequency range as expected since they are all –CH or 
tertiary carbons. The mass spectra gave the expected molecular ion peak with an M/Z ratio of 
252.78 at 100.0% of the baseline. The melting point of the compound was found to be 142-













2.7.2.2. Synthesis of 1-phenyl-3-[4-(2-pyridinyl) thiazol-2-yl) urea, RIZ 020C 
This compound was synthesised by stirring phenylisocyanate and FM002 at 560C for two hours, 
and then the heat was turned off and the reaction mixture left to stir at room temperature for 
24 hours (Scheme 1.3). The phenylisocyanate was generated in situ by refluxing aniline and 
triphosgene in toluene for 8 hours, then cooling the mixture to 0oC using ice before the addition 
of the amine FM002.  
 




C, 8 hr; (ii) 56
o
C   RT, 26 hr. 
Overnight the desired product precipitated out, and was recrystallized from absolute ethanol to 
yield the final pure product which was isolated as a pale-brown solid in 27% yield. The 
generation of the phenylisocyanate occurs via a nucleophilic substitution reaction while the last 
step to form the final compound is thought to be a nucleophilic addition reaction as depicted in 
figure 3.9. 
 












2.7.2.3. Synthesis of N-[4-(2-pyridinyl) thiazol-2-ylcarbamothioyl) benzamide, RIZ 020F 
The final target compound in this series was synthesized by refluxing commercially available 
benzoyl isothiocyanate and the amine FM002 in acetone for 3 hours (Scheme 1.4) to yield the 
product as a pale green solid in 51% yield. 
 




C, 3 hr.  
The reaction follows the same mechanism as the final step of the reaction mechanism 

























2.8. Physicochemical Properties, Pharmacological and Cytotoxicity Evaluation, and 
Microsomal Metabolic Stability Profiling 
2.8.1 Physicochemical Properties 
Physicochemical properties of a drug have an effect on the drug's pharmacological activity, and 
play an important role in the Absorption, Distribution, Metabolism, and Excretion (ADME) 
properties of the drug. Solubility is one of the most significant physicochemical properties of a 
drug candidate, and has long been noted as a limiting factor in the absorption process since 
only compounds in solution are readily available for permeation across the gastrointestinal 
membrane. Solubility is therefore related to the drugs’ permeability and subsequently its 
pharmacological activity. However, there needs to be a balance betwee  the solubility and 
lipophilicity of a drug to enable it not only be absorbed but to cross cell membranes and be 
effectively distributed.66 
In this study the solubility of the synthesized compounds was determined experimentally by the 
turbidimetric assay and classified using the data described by Lipinski67 as 
 ≤  5 µg/ml = low solubility 
 10-60 µg/ml = medium solubility 
 ≥ 65 µg/ml = high solubility 
Drug candidates with low aqueous solubility can yield misleading results during assays, with an 
increased risk of false hits and/or leads. Low solubility is typically associated with high plasma 
protein binding, slow tissue distribution, and drug-drug interactions generally leading to low 
biological activity. High solubility is desirable up to a certain limit beyond which permeability, 
and therefore activity, is decreased. It is therefore important to determine the solubility of 
compounds at an early stage of the drug development process to get an indication of the 
necessary balance required for activity and to avoid the risk of false hits or leads.66  
From the results obtained  it was observed that all the compounds in series 1 had low to 
moderate solubility, (Table 1.3), based on the nature of the substituent attached. Solubility is 
inversely proportional to the number and type of lipophilic functions within the molecule and 



































    
14.0 RIZ020 








































   
23.0 
Based on the Craig plot substitutions, the electronic effect of the substituents didn’t have 












solubility to an extend as compounds with lipophilic groups such as halides had lower solubility 
compared to those with hydrophilic groups such as acetyl, or methylsulfonyl. Solubility was 
improved when the substituted phenyls were replaced by other heterocycles like the pyridine, 
thiophene, thiazole, and imidazole. 
Series 2 compounds had moderate solubility (Table 1.4) probably due to the balance of the 
hydrophilic pyridine ring and the lipophilic bromo-substituted phenyl ring.  
Table 1.4: Solubility of series 2 and 3 compounds 
                                                              





















   RIZ020F 
 
3 
The solubility of compounds in series 3 decreased as the linker changed from an amine to urea, 
to acyl thiourea (Table 1.4) .These compounds were all less soluble than their amide analogue. 
This is probably due to the increase in tightness of the crystal packing of the molecule as the 
molecules tendancy for hydrogen bonding increased. 
2.8.2 Pharmacological and Cytotoxicity Evaluation 
The in vitro antimycobacterial activity of the synthesized compounds was measured in a micro 












microorganism) was determined for all the compounds against Mycobacterium tuberculosis 
H37Rv strain. Rifampicin and Kanamycin were used as references for the assay. 
The in vitro antiplasmodial activity of the compounds was performed in triplicate on one 
occasion against the chloroquine sensitive (CQS) NF54 strain of Plasmodium falciparum. 
Chloroquine (CQ) was used as the reference drug in the assay. The cytotoxicity was tested 
against a mammalian Chinese Hamster Ovarian (CHO) cell-line using the 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazoliumbromide (MTT) assay. 
2.8.2.1 Series 1 and 2 
 
Antimycobacterial activity 
The results obtained showed that compound in this series are active against M.tb within a 
range of between 1.25µM to 160µM. This activity is best with the phenyl substituted 
compounds with no significant variation based on the type of substituent at the para position 
(Table 1.5). This implies that the electronic effect and the hydrophobicity of the substituents 
didn’t have an effect on activity. Compound RIZ 003 had the best day 14 activity of 2.5µM. The 
non variation in activity could be due to the fact that the MIC99 values reported were 
determined based on a two-fold serial dilution of concentrations and not exact concentrations 
such that an MIC99 of 20µM represents concentrations of 10µM ≤ MIC99 ≤ 20 µM. This can be 
ruled out in future work where exact MIC99 values will be determined. It could also be that the 
activity is not dependent on whether the substituent on the phenyl ring is electron withdrawing 
or donating. 
The position of the substituent, however, seems to have an effect on activity as demonstrated 




























Day 7 Day 14 
RIZ 003 
 
2- 5.3 (1.9) 3.6 (1.3) 0.7 1.25 2.5 
RIZ 034 
 
3- 15.9 (5.7) 89.0 (32.1) 5.6 >160 >160 
RIZ 035 
 
4- 3.5 (1.3) 34.4 (12.4) 9.8 >160 >160 
RIZ 004 
 
2- 3.9 (1.6) 7.9 (3.2) 2.0 5 5 
RIZ 006 
 
2- 5.9 (2.1) 19.7 (7.1) 3.3 10 20 
RIZ 007 
 
2- 14.8 (4.8) 2.1 (0.7) 0.1 10 10 
RIZ 008 
 
























Day 7 Day 14 
RIZ 009 
 
2- 6.1 (2.0) 2.2 (0.7) 0.4 5 5 
RIZ 010 
 
2- 18.6 (6.5) 2.0 (0.7) 0.1 5 5 
RIZ 011 
 
2- 5.5 (2.0) 23.3 (8.5) 4.2 2.5 5 
RIZ 012 
 
2- 6.5 (2.0) 6.5 (2.0) 1.0 2.5 5 
RIZ 013 
 
2- 7.4 (2.5) 3.4 (1.1) 0.5 20 20 
RIZ 015 
 
2- 7.6 (2.5) 4.5 (1.5) 0.6 5 5 
RIZ 017 
 
2- 1.3 (0.4) 3.2 (1.0) 2.5 5 5 
RIZ 018 
 
2- 1.8 (0.5) 3.1 (0.9) 1.7 5 5 
RIZ 020 
 
2- 1.0 (0.3) 3.0 (0.9) 3.0 5 5 
RIZ 021 
 
























Day 7 Day 14 
RIZ 022 
 
2- 1.6 (0.6) 2.8 (1.0) 1.8 2.5 5 
RIZ 023 
 
2- >35.4 (>10) 9.2 (2.6) 0.3 80 80 
RIZ 024 
 
2- >35.4 (>10) 0.7 (0.2) 0.02 10 10 
RIZ 025 
 
2- 1.9 (0.5) 0.0 (0.004) 0.005 5 5 
RIZ 038 
 
2- 13.8 (4.0) 14.3 (4.1) 1.0 160 160 
RIZ 039 
 
2- 35.0 (9.5) 1.4 (0.4) 0.04 160 160 
RIZ 042 
 
2- 0.9 (0.2) 2.8 (0.8) 3.1 *10 40 
FM 002  2- 47.8 (8.5) 55.0 (9.8) 1.2 >160 >160 
Selectivity index (SI) = IC50µM CHO/IC50µM NF54            * Precipitation 
The solubility of the compounds didn’t influence activity as most of the active compounds were 
poorly solube. Activity in this series decreased when the phenyl ring was replaced with other 












The 2-amino-4-(2-pyridyl) thiazole scaffold FM002 was also tested along with the synthesized 
derivatives and was found to have an IC50 value of >160µM. This decreased activity compared 
to the other derivatives may be attributed to the fact that it doesn’t contain any phenyl 
substitution at the 2-amino position of the thiazole ring. This therefore suggests that a 
substituted phenyl group at this position is essential for activity. 
When the 2-pyridyl group at position 4 of the thiazole ring was replaced by the 3-pyridyl and 4-
pyridyl analogues in series 2, activity was lost. This suggests that the 2-pyridyl group at this 
position is essential for antimycobacterial activity. 
Antiplasmodial activity 
The results showed that compounds in series 1 were active against the chloroquine sensitive 
(CQS) NF54 strain of Plasmodium falciparum with IC50 values in the range of 0.2µg/ml to 
10µg/ml (Table 1.5). This activity was best when the phenyl group is substituted with 
hydrophobic electron withdrawing groups, moderate when the phenyl group is substituted with 
hydrophilic electron withdrawing groups and least when the phenyl group is substituted with 
hydrophobic electron donating groups. The exception, however, was the most active 
compound RIZ 008 which had an IC50 value of 0.8µM and contained a phenyl group substituted 
with a para-hydrophilic electron withdrawing -CN group. This suggests that the activity is 
influenced by the electronic effect of the substituent than its hydrophobocity. 
The position of the substituent had an effect on activity as demonstrated by the bromo 
substituted compounds where activity of the meta-bromo > ortho-bromo > para-bromo. The 
solubility of the compounds didn’t influence activity as some of the most active compounds 
were poorly solubility. Activity in this series decreased when the phenyl ring was replaced with 
other heterocycles like the 2-pyridine, 3-pyridine, thiazole, and imidazole. The thiophene and 4-
pyridine ring, however, retained activity. 
The 2-amino-4-(2-pyridyl) thiazole scaffold FM002 was also tested along with the synthesized 












other derivatives may suggest that a phenyl substitution at the 2-amino position of the thiazole 
ring may be essential for activity. 
The antiplasmodial activity did not change significantly when the 2-pyridyl group at position 4 
of the thiazole ring was replaced by the 3-pyridyl or 4-pyridyl in series 2. This suggests that the 
aryl group at this position may not be essential for antiplasmodial activity. 
2.8.2.2 Series 3 
Antimycobacterial activity 
Varying the linker between the thiazole moiety and the substituted phenyl group from the 
amide to the amine, urea, and acylthiourea in series 3, resulted in compounds that were less 
active than the parent amide derivative (Table 1.6).  











Activity MIC99 (µM) 
  Day 7 Day 14 
RIZ 020B 
 
3.2 (0.8) 1.3 (0.4) 0.4  160 160 
RIZ 020C 
 
1.7 (0.5) 2.2 (0.7) 1.3  *10 80 
RIZ 020F 
 
2.7 (0.9) 4.3 (1.5) 1.6  *20 80 












As mentioned previously these compounds were all less soluble than their amide analogue and 
two of them precipitated out during testing making them not readily available in solution to 
exert activity on the M.tb. 
Antiplasmodial activity 
The antiplasmodial activity did not change significantly when linker was changed from amide to 
amine, urea, and acylthiourea in series 3. This suggests that the linker is not critical for the 
activity of the compounds. All tested compounds were less active than the reference drugs 
used and showed significant cytotoxicity on the (CHO) cell line and therefore had a low 
selectivity index. The antiplasmodial activity may therefore be due to the cytotoxic nature of 
the compounds and not due to any intrinsic antiplasmodial activity. 
2.8.3 Metabolic Stability Profiling 
The in vitro metabolic stability of a selected sample of the compounds was determined in 
human liver microsomes (HLM), rat liver microsomes (RLM), and mouse liver microsomes 
(MLM) separately. The samples were selected based on their antiplasmodial activity. Only 
compounds with an IC50 value of ≤ 2.0µM were tested.  
Metabolic reactions were initiated by the addition of the co-factor NADPH to a mixture of the 
microsomes and the test compounds and incubated for 30 minutes. 
From the obtained data, with the exception of RIZ022, the selected compounds exhibited 
instability across all species (Table 1.7). In addition RIZ 017 and RIZ 018 also show significant 



















Table 1.7: Metabolic Stability of Some Derivatives in Human, Rat, and Mouse Liver Microsomes. 
 
Compound R1 R2 % remaining 
HLM RLM MLM 
RIZ 008 
 
   
      24.1             64.6             1.61 
RIZ 017 
 
   




       14.2            72.1               3.61 
RIZ 020 
 
     
        27.5          54.5               7.60 
RIZ 022 
 
     
          >99           >99              82.4 
RIZ 025 
 
     

















The SAR (Structure-Activity Relationship) study was conducted on the 2-amino-4-aryl thiazole 
scaffold by synthesizing a series of analogues with different motifs at the various positions of 
the scaffold.  
The compounds were characterized using various spectroscopic and analytical techniques, such 
as 1H, and 13C NMR, melting point and mass spectrometry. Solubility of the compounds was also 
determined to establish its effect, if any, on the activity. The antiplasmodial, cytotoxicity and 
antimycobacterial activities as well as microsomal metabolic stability of the compounds were 
evaluated in vitro.  
The compounds exhibited moderate antiplasmodial activity in the CQS strain of P. falciparum, 
and good antimycobacterial activity on the H37Rv strain of M.tb. It can be concluded that the 2-
pyridyl group at position 4 of the thiazole ring is essential for antimycobacterial activity as is the 
presence of a substituted phenyl at position 2. The electronic effect of the substituents based 
on the Craig plot had no influence on either the solubility or the antimycobacterial activity of 
the compounds. However, the antiplasmodial activity was better with electron withdrawing 
substituents. The hydrophobicity of the substituents affected neither the antimycobacterial nor 
the antiplasmodial activity of the compounds but influenced their solubility as expected.  
The linker between these two groups seems to affect solubility and hence antimycobacterial 
activity with little influence on the antiplasmodial activity. The antiplasmodial activity though 
good, could not be ascertained as intrinsic to the compounds due to their cytotoxic nature.  
Most of the compounds had low to moderate solubility depending on the motifs attached to 
the scaffold. Most of the compounds were also unstable in HLM, RLM, and MLM, as well as in 
buffer. 
An expansion of the SAR of this scaffold, to cover a wider chemical space and diversity, may be 













CHAPTER 3: Design, Synthesis and Pharmacological evaluation of Metergoline Derivatives 
3.1 Introduction  
This chapter describes the design, synthesis and characterization of some new metergoline 
derivatives. Metergoline can be chemically viewed as an amine with a carboxybenzyl protecting 
group (Figure 4.0). The first step towards derivatization is therefore the removal of the 
carboxybenzyl protecting group to release the free amine that can then be derivatized. All 
synthesized derivatives were evaluated for in vitro antimycobacterial and antiplasmodial 
activity as well as cytotoxicity, and profiled for their solubility and  microsomal metabolic 
stability.  
 
Figure 4.0: Chemical structure of metergoline 
3.2 Background 
Metergoline is a semi-synthetic ergoline alkaloid derived from the ergoline backbone (Figure 
4.1). It is in clinical use for the management of hyperprolactinaemia and as a prophylaxis for 
migraine headaches.68 Ergoline occurs naturally in lower fungi. 
 












Ergoline alkaloids and their derivatives have broad clinical use such as: vasoconstriction in 
treatment of migraines (ergotamine),69 management of Parkinson’s disease (bromocriptine ),70 
and as oxytoxics (ergometrine) 71 (Figure 4.2).  
 
Figure 4.2: Chemical structures of drugs with an ergoline backbone in clinical use 
Metergoline has been documented to have in vitro antifungal activity,72,73 and has been 
investigated in the management of psychiatric disorders like obsessive compulsive disorder, 
carbon dioxide induced anxiety and premenstrual syndrome.68,74–76 There is hardly any 
literature on its investigation as an antimicrobial or antiplasmodial agent, however, a HTS 
conducted by the TAACF on a vast library of compounds in 2009, found  metergoline to have 
antimycobacterial activity with a MIC90 of between 5.6-6.0µg/ml.
77 In addition, a quantitative 
HTS for delayed death inhibitors of the malaria parasite plasmid, on a National Institute of 
Health (NIH) molecular library found metergoline to have antiplasmodial activity with an IC50 of 
7.4µM.78 
3.3 Rationale             
There are a good number of compounds with an ergoline backbone in diverse clinical use as 
mentioned.68–71 Metergoline being one of them demonstrated antimycobacterial activity in a 
HTS conducted by the TAACF, and antiplasmodial activity in a HTS for delayed death inhibitors 
of the malaria parasite plasmid on a NIH library as mentioned above.77,78  Although there were 












starting point for drug repositioning through medicinal chemistry. There are no reports on any 
further studies on the potential of this compound and its derivatives as antimycobacterial 
and/or antiplasmodial agents after the HTS campaigns mentioned above. A clear advantage is 
that being in clinical use, the human system profile of the drug, and that of the ergoline 
backbone are already known thus making it attractive for repositioning. It was thus envisioned 
that structural modification could yield compounds with better antimycobacterial and 
antiplasmodial activity than the parent drug.  
In this study, the ergoline backbone of metergoline was maintained and substitutions made on 
the free primary amine by incorporating various substituted aromatic rings. The QSAR 
approach59 was used in determining the substituent on the aromatic ring.  
3.4 Objective 
To perform structural modifications on the ergoline backbone of metergoline, with a view to 
improving antimycobacterial and antiplasmodial activity and deriving analogues with favorable 
drug metabolism and pharmacokinetic properties. 
3.4.1 Research Question 
Is it possible to identify metergoline derivatives with potent antimycobacterial and/ or 
antiplasmodial activity and favorable drug metabolism and pharmacokinetic properties? 
3.4.2 Specific Aims: 
1. Synthesis of target compounds 
2. Characterization of the target compounds using analytical and spectroscopic techniques 
3. Conducting in vitro solubility profiling of synthesized compounds 
4. Evaluating synthesized compounds for pharmacological (antimycobacterial and 
antiplasmodial) activity. 
5. Performing in vitro microsomal metabolic stability profiling of the most potent 













3.5 Introduction, Synthesis and Characterization of metergoline derivatives  
3.5.1 Introduction 
As already mentioned, metergoline is made up of an ergoline backbone and a carboxybenzyl 
group. Since this compound has these two distinct features the analogues synthesised were 
decided upon with the goal of retaining the similarity in features but with addition of groups 
that may improve activity. 
3.5.2. Synthesis of the 4-R-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-
fg]quinolin-9-yl)methyl)benzamides 
The desired benzamides were synthesized in a 2-step reaction sequence starting from 
commercially available metergoline which was catalytically cleaved by hydrogenation using 
Pd/C catalyst at room temperature (Scheme 1.5) to remove the benzyloxycarbamate group and 
yield the free amine FRM000. 
 
Scheme 1.5: Reagents and conditions; (i) EtOH:THF (1:1), H2, 10% wt Pd/C, RT, 10 hr; (ii) Carboxylic acid, EDCI, 
HOBt, DCM, RT, 24 hr. 
The second and final step of this reaction is an EDCI-mediated coupling of FRM000 with a range 
of different appropriately substituted phenyl carboxylic acids. This was achieved by adding the 
EDCI in small portions to a solution of the appropriate carboxylic acid and HOBt in anhydrous 
DCM and letting this reaction mixture to stir for 10 minutes and then the primary amine 
FRM000 was added as a solution in dry DCM (Scheme 1.5). The reaction mixture was then left 
to stir for 24 hours at room temperature and the different benzamides isolated as solids in 












Table 1.8: Isolated yields, molecular ion peaks and melting points of 4-R-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-
octahydroindolo[4,3-fg]quinolin-9-yl)methyl)benzamides 
 
Compound code R % YIELD 
[M]+ Melting Point 
(o C) Expected Found 
FRM 001 Br 53 451.13       450.98 213-215 
FRM 002 CH2CH3 37 401.25        401.07 192-194 
FRM 003 CN 52 398.21        397.99 137-139 
FRM 004 NO2 37 418.20        417.93 228-230 
FRM 005 Cl 35 407.18        406.87 224-226 
FRM 006 N(CH3)2 78 416.26        415.92 258-260 
FRM 007 (CH2)3CH3 38 429.28        428.91 171-173 
FRM 008 SCH3 31 419.20        418.81 214-216 
FRM 009 I 46 499.11        498.98 227-229 
FRM 010 SO2CH3 44 451.19        451.16 209-211 
FRM 011 OCH3 41 403.23        403.12 212-214 
FRM 012 CF3 43 441.20        440.94 228-230 
FRM 013 COCH3 41 415.23        414.79 198-200 
FRM 014 F 28 391.21        391.18 212-214 
FRM 015 H 27 373.22        373.13 205-207 












Spectroscopic Analysis of key intermediates and the final target compounds. 
As the benzamides are derivatives of the ergoline backbone they contain the characteristic 
features as described for the key intermediate FRM000, and additional features based on the 
substituted phenyl group added. These additional features helped ascertain that the coupling 
to form the amides had successfully occurred. Since all compounds in this series contained the 
ergoline backbone, an amide linker, a phenyl ring substituted at the para position, only one 
representative compound is described here.  
The 1H NMR spectrum of FRM000 is comparable to that reported in literature (Figure 4.3).79 It 
has four characteristic aromatic protons as expected for H2, H10, H11 and H12. It shows two 
sharp singlets corresponding to the methyl groups H1 and H5 at chemical shift values of 3.71 
ppm and 2.44 ppm respectively. H1 is more downfield by virtue of being attached to a nitrogen 
atom of an aromatic ring system. The aliphatic protons are in the region of 1.0-3.5 ppm as 
expected. The –NH2 appeared upfield at approximately 1.75ppm. The 
13C NMR spectrum 
contains 17 carbon atoms as expected with the methyl carbons appearing slightly downfield 
due to being directly attached to a nitrogen atom. The mass spectra gave the expected 
molecular ion peak with an M/Z ratio of 269.15 at 100% of the baseline.  
The 1H NMR spectrum of FRM012 shows the disappearance of the NH2 protons of the amine 
group and the appearance of the NH proton of the amide group lying downfield at a chemical 
shift value of 6.36 ppm, indicating the successful coupling between the amine and the 
carboxylic acid (Figure 4.3). The aromatic protons of the ergoline backbone appear as in 
















H NMR of FRM000 in CDCl3 at 400 MHZ (top). 
1
H NMR of FRM012 in CDCl3 at 400 MHZ (bottom) 
The appearance of two doublets H14 and H15 representing the two sets of equivalent protons 
of the substituted phenyl ring further confirming successful coupling. 13C NMR spectrum 
indicates that all the expected carbons are present. The most downfield carbon at a chemical 
shift value of 166.47 ppm corresponds to the carbonyl carbon. The mass spectra gave the 














3.5.3. Synthesis of the 4-chloro-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-
fg]quinolin-9-yl)methyl)aniline, FRM017. 
To investigate the importance of the linker between the ergoline backbone and the substituted 
phenyl group, an analogue of FRM005 was synthesized with an amine linker. This was achieved 
via reductive amination where FRM000 and 4-chlorobenzaldehyde were stirred for 2 hours at 
room temperature in dry DCM under nitrogen (Scheme 1.6), then cooled to 0oC using ice. 
Sodium borohydride was then added to the imine generated in situ and the reaction left to 
warm to room temperature again and stirred for 24 hours. The final compound FRM017 was 
isolated as a brown solid in moderate yield. 
 
Scheme 1.6: Reagents and conditions; (i) N2, DCM, RT→0
o
C, 2 hr; (ii) NaBH4, RT, 24 hr. 
Spectroscopic Analysis of FRM017 
The 1H NMR spectrum shows the disappearance of the NH2 protons of the primary amine group 
and the appearance of the NH proton of the secondary amine group lying upfield at a chemical 
shift value of 1.8 ppm, indicating a successful reductive amination (Figure 4.4). The ergoline 
backbone protons appear as in FRM000 with some slight variation in the chemical shifts, 
however, the pattern is maintained. The appearance of a doublet at 7.34 ppm integrating for 
four protons corresponding to H15 and H16 further confirms a successful reaction. In addition 
there is the appearance of a doublet at a chemical shift value of 3.84 ppm corresponding to 







































3.6. Physicochemical Properties, Biological and Cytotoxicity Evaluation, and Microsomal 
Metabolic Stability Profiling 
3.6.1 Physicochemical Properties 
The solubility of the compounds was determined experimentally by the turbidimetric solubility 
assay and classified as  
 ≤  5 µg/ml = low solubility 
 10-60 µg/ml = medium solubility 
 ≥ 65 µg/ml = high solubility67 
The results obtained showed that the compounds had low to moderate solubility (Table 1.9). 
Table 1.9: Solubility of metergoline amide analogues 
 
Compound code R 
Solubility 
(µg/mL) 
Compound code R 
Solubility 
(µg/mL) 
FRM 001 Br 4.0 FRM010 SO2CH3 12.0 
FRM002 CH2CH3 33.0 FRM011 OCH3 45.0 
FRM003 CN 14.0 FRM012 CF3 29.0 
FRM004 NO2 6.0 FRM013 COCH3 14.0 
FRM005 Cl 12.0 FRM014 F 56.0 
FRM006 N(CH3)2 3.0 FRM015 H 45.0 
FRM007 (CH2)3CH3 5.0 FRM016 OCF3 56.0 
FRM008 SCH3 4.0 Metergoline   32.0 














The free amine FRM000 had a moderate solubility of 54µg/ml, while the compound FRM017 
which is an analogue of FRM005 with an amine linker had a high solubility of 79µg/ml. This can 
be explained by the presence of the primary and secondary amine respectively which makes 
them hydrophilic due to the availability of the lone pair of electrons. The parent compound 
metergoline had a moderate solubility of 32µg/ml. 
3.6.2 Pharmacological and Cytotoxicity Evaluation 
In vitro Antimycobacterial Activity 
The results obtained showed that compounds were active against M.tb H37Rv strain (Table 2.0) 
within MIC99 values in the range of 19µM-50µM. This suggests that the carboxybenzyl 
protecting group is not essential for activity. Activity is best with compounds that have the 
phenyl ring substituted with a hydrophobic electron withdrawing or donating group. This 
suggests that the electronic property of the substituent had no influence on activity. The 
hydrophobicity of the substituents, however, influenced activity since compounds that had 
hydrophilic substituents were less active than those with hydrophobic substituents. The 
hydrophobicity of the substituent may be enhancing activity by aiding the transport of the 
compounds across the cell wall and cell membrane of M.tb to the site of action. The free amine 
FRM000 was also tested alongside the synthesized analogues and was found to be inactive at 
the maximum concentration of 50µM, suggesting that the presence of an aryl group attached 
to the nitrogen of the amine is essential for activity. However, since all compounds were less 
active than the parent metergoline (based on reported literature values), optimization of the 
aryl group is needed for optimized activity. 
In vitro Antiplasmodial and Cytotoxicity Activity 
The compounds were active against the chloroquine sensitive (CQS) NF54 strain of Plasmodium 
falciparum with IC50 values in the range of 0.5µM-34µM (Table 2.0). Compounds with 
hydrophobic substituents were more active than those with hydrophilic substituents with the 
exception of the most active compound FRM003 which had a hydrophilic substituent. The 
























Activity MIC99 (µM) 
  Day 14 Day 21 
FRM 001 Br 2.6 (1.2) 5.1 (2.3) 2.0  19 25 
FRM 002 CH2CH3 4.3 (1.7) 5.6 (2.2) 1.3  19 25 
FRM 003 CN 0.6 (0.2) 103.6 (41.3) 187.7  37 50 
FRM 004 NO2 0.5 (0.2) 5.0 (2.1) 10.7  37 50 
FRM 005 Cl 1.3 (0.5) 4.3 (1.7) 3.3  19 25 
FRM 006 N(CH3)2 33.8 (14.1) 132.5 (55.2) 3.9  25 50 
FRM 007 (CH2)3CH3 2.0 (0.9) 14.5 (6.2) 7.3  19 25 
FRM 008 SCH3 4.7 (2.0) 6.0 (2.5) 1.3  19 50 
FRM 009 I 3.0 (1.5) 5.5 (2.7) 1.8  19 25 
FRM 010 SO2CH3 14.2 (6.4) 221.5 (100) 15.6  37 >50 
FRM 011 OCH3 8.4 (3.4) 7.4 (3.0) 0.9  19 37 
FRM 012 CF3 2.7 (1.2) 4.9 (2.2) 1.8  19 37 
FRM 013 COCH3 12.3 (5.1) 151.9 (63.1) 12.4  19 50 
FRM 014 F 12.5 (4.9) 7.3 (2.9) 0.6  37 50 
FRM 015 H 24.4 (9.1) 27.0 (10.1) 1.1  37 50 
FRM 016 OCF3 4.2 (1.9) 12.8 (5.8) 3.1  25 50 
*FRM 017 Cl 0.4 (0.15) 3.3 (1.3) 8.7    
Unsubstituted 
amine 
 3.6 (1.0) 26.1 (7.0) 7.0  50 >50 
Metergoline   3.7 (1.5) 16.6 (6.7) 4.5  ND ND 












Compounds which had the phenyl ring substituted with a hydrophobic group showed significant 
cytotoxicity on the CHO cell line and therefore had a low selectivity index while those with 
hydrophilic groups had a good selectivity index. The activity of these compounds could 
therefore be due to their cytotoxic effect. Metergoline and the free amine FRM000 had IC50 of 
3.7µM and 3.6µM respectively. The derivatization of the amine was thus beneficial as it gave 
some analogues with improved activity. 
The best combination of activity and selectivity was compound FRM003 with an activity of 
0.6µM and a selectivity index of 188. This compound contained a phenyl ring substituted with a 
para-hydrophilic electron withdrawing a -CN group. FRM017 with an amine linker was found to 
have an IC50 of 0.4µM and a selectivity index of 8.7 suggesting that the linker does not affect 
activity. 
3.6.3 Metabolic Stability Profiling 
The in vitro metabolic stability of the compounds was determined in human liver microsomes 
(HLM) and mouse liver microsomes (MLM) separately. Metabolic reactions were initiated by 
the addition of the co-factor NADPH to a mixture of the microsomes and the test compounds 
and incubated for 30 minutes. 
From the obtained data, based on the HLM results, compounds with hydrophobic electron 
withdrawing and hydrophilic electron withdrawing substituents had better stability than those 
with hydrophobic electron donating groups (Table 2.1). Aromatic hydroxylation generally 
parallels electron density80 with compounds having greater electron density undergoing faster 
metabolism. This may explain why electron withdrawing substituents increased metabolic 
stability,81 assuming that metabolism proceeds through aromatic hydroxylation for these 
compounds. FRM017 with an amine linker instead of an amide was unstable compared to its 
amide analogue FRM005. Metergoline was found to be unstable, and derivatization was 


















R X % remaining Compound 
code 
R X % remaining 
HLM MLM  HLM MLM  
FRM 001 Br O 60 82  FRM009 I O 78 >99  
FRM002 CH2CH3 O 45 61  FRM010 SO2CH3 O >99 95  
FRM003 CN O 68 44  FRM011 OCH3 O 58 82  
FRM004 NO2 O 69 >99  FRM012 CF3 O 90 >99  
FRM005 Cl O 54 >99  FRM013 COCH3 O 44 92  
*FRM 017 Cl CH2 22 38  FRM014 F O 20 78  
FRM006 N(CH3)2 O ND ND  FRM015 H O 5 63  
FRM007 (CH2)3CH3 O 22 >99  FRM016 OCF3 O 79 >99  
FRM008 SCH3 O 14 50  metergoline   1.2 20  



















Structural modifications were performed on the ergoline backbone of metergoline, and a 
number of analogues synthesized with different para substituted phenyls. 
The compounds were characterized using various spectroscopic and analytical techniques, such 
as 1H, and 13C NMR, melting point and mass spectrometry. Solubility of the compounds was also 
determined using the turbidimetric solubility method. The antiplasmodial, cytotoxicity and 
antimycobacterial activities as well as microsomal metabolic stability of the compounds were 
evaluated in vitro.  
The compounds exhibited moderate antiplasmodial activity in the CQS strain of P. falciparum, 
and moderate antimycobacterial activity on the H37Rv strain of M.tb. The electronic effect of 
the substituent didn’t have an influence on antimycobacterial activity while the hydrophobicity 
did have an effect since compounds that had hydrophilic groups were less active than those 
with hydrophobic groups. The presence of a substituted phenyl group attached to the nitrogen 
atom of the amine was found to be essential for antimycobacterial activity as the free 
unsubstituted amine was inactive at the maximum concentration of 50µM. The substituted 
phenyl group however didn’t confer optimum activity as the compounds were less active than 
metergoline, hence a wider chemical space should be investigated. The antiplasmodial activity 
of the compounds wasn’t influenced by the electronic property of the aromatic substituents 
whereas the hydrophobicity of the substituents enhanced activity although with significant 
cytotoxicity. Changing the linker to an amine group didn’t have any significant effect on 
antiplasmodial activity. Derivatization led to analogues with better antiplasmodial activity than 
metergoline. As expected compounds with hydrophobic electron withdrawing substituents had 
better microsomal metabolic stability than those with hydrophobic electron donating groups. 
An expansion of the diversity of structural motifs on the ergoline backbone to cover a wider 
chemical space may be useful in establishing SAR and aid the design and synthesis of more 
potent and metabolically stable derivatives. In addition further work will include ortho and 












CHAPTER 4: Summary and Future Prospects 
4.1 General Summary and Conclusion 
A SAR study was conducted on the 2-amino-4-aryl thiazole scaffold by synthesizing a series of 
analogues with different motifs at the various positions of the scaffold. Structural modifications 
were performed on the ergoline backbone of metergoline, and a number of analogues were 
synthesized with different substituted phenyls. 
Standard organic synthetic routes were used and the compounds characterized using various 
spectroscopic and analytical techniques, such as 1H, and 13C NMR, melting point and mass 
spectrometry to ascertain their identity. Aqueous solubility of the compou ds was determined 
experimentally by the turbidimetric solubility method. The in vitro antiplasmodial, cytotoxicity 
and antimycobacterial activities as well as the microsomal metabolic stability of the compounds 
were also evaluated. 
In vitro results from the 2-amino-4-aryl thiazole scaffold studies indicate that,  
i. For antimycobacterial activity: 
 The 2-pyridyl moiety at position 4 of the thiazole ring is essential 
 A substituted phenyl ring at the 2-amino position of the thiazole ring enhanced activity 
with the  electronic effect and hydrophobicity of the substituent on the phenyl ring 
having no effect on activity 
 The solubility of the compounds was influenced by the hydrophobicity of the 
substituents 
 The linker between the thiazole moiety and the substituted aryl group via position 2 of 
the thiazole moiety affected solubility.  
ii. For antiplasmodial activity: 
 The group attached at position 4 of the thiazole ring did not influence activity 
 A substituted phenyl ring at the 2-amino position of the thiazole ring enhanced activity 
with electron withdrawing substituents being the most active, while the hydrophobicity 












 The solubility of the compounds was influenced by the hydrophobicity of the 
substituents 
 The linker between the thiazole moiety and the substituted aryl group via position 2 of 
the thiazole moiety did not affect activity. 
The compounds had low to moderate solubility depending on the motifs attached to the 
scaffold and were unstable in HLM, RLM, and MLM. 
In vitro results from the metergoline analogues suggests 
iii. For antimycobacterial activity: 
 The presence of a substituted phenyl ring attached to the nitrogen of the amine 
enhanced activity as the unsubstituted amine was inactive 
 The  electronic property of the substituent  on the phenyl ring had no effect on activity 
while the hydrophobicity enhanced activity 
 The solubility of the compounds  had no effect on activity  
 The linker between the ergoline backbone and the substituted phenyl ring did not affect 
activity. 
iv. For antiplasmodial activity 
 The presence of a substituted phenyl ring attached to the nitrogen of the amine was  
not essential for activity as the unsubstituted amine was active 
 The  electronic property of the substituent  on the phenyl ring had no effect on activity 
while the hydrophobicity enhanced activity 
 The solubility of the compounds had no effect on activity 
 The linker between the ergoline backbone and the substituted phenyl ring did not affect 
activity. 
Compounds with hydrophobic substituents had moderate solubility while those with 
hydrophilic groups had high solubility. Compounds with electron withdrawing substituents had 













4.2 Future Outlook 
An expansion of the SAR of the 2-amino-4-aryl thiazole scaffold and the structural modifications 
on the ergoline backbone, to cover a wider chemical space and incorporate chemical diversity, 
may be useful in future to draw detailed and useful insight as to the drivers of the SAR. In 
addition, testing the compounds against chloroquine and multi-drug resistant strains of P. 
falciparum and clinical isolates of drug resistant M.tb will give an indication of the usefulness of 
these compounds for investigation for drug resistant cases of malaria and tuberculosis. Lastly 
ortho and meta derivatives of some of the synthesized metergoline analogues will be 
































CHAPTER 5: Experimental 
5.1. General comments 
All reagents and solvents were obtained from commercial sources and used as received. All dry 
solvents were obtained from an SP-1 stand alone solvent purification system from LC 
Technology Solutions Inc. Reactions were monitored by thin layer chromatography (TLC) using 
Merck TLC silica gel 60 F254 aluminium-backed precoated plates and were visualized by 
ultraviolet light at 254 nm.  
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Varian Unity XR400 MHz (1H at 
400 MHz, 13C at 100 MHz), or a Bruker Ultrashield 400 Plus spectrometer (1H at 400 MHz, 13C at 
100 MHz). Chemical shifts for 1H and 13C NMR were reported using tetramethylsilane (TMS) as 
the internal standard. NMR data is presented as chemical shift in ppm on the δ scale relative to 
δTMS = 0, intergration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, and m = 
multiplet), coupling constant (J/ Hz).COSY experiments were used in some cases to fully 
interpret spectra for related compounds. 
Melting points were determined using a Reichert-Hung Thermovar Hot Stage Microscope and 
are uncorrected. Mass Spectrometry was recorded on a JEOL GCmatell in Electron Ionisation 
mode. High Performance Liquid Chromatography (HPLC) was done using a Waters HPLC 2727 
instrument with a Waters 2424 PDA detector and a Waters X-bridge C18 column (19mm x 
250mm x 5µM, preparative). HPLC grade solvents were used to prepare 10mMol ammonium 
acetate in water and 10mMol ammonium acetate in methanol which were used as eluents. 
The HPLC-MS system used for metabolic stability assay was Agilent 1200 Rapid Resolution (600 
bar) HPLC with a diode array detector (DAD) coupled to an AB SCIEX 4000 QTRAP MS, equipped 
with a Turbo V™ ion source. Analyst 1.5.1 software was used for instrument control and data 














5.2. Synthesis of 4-R-N-[4-(2-pyridinyl)-2-thiazolyl]–benzamides 
5.2.1. General procedure for the synthesis of 2-bromo-1-(pyridin-2-yl) ethanone (FM001) 
To a solution of 2-acetylpyridine (16.5 mmol) in 48% HBr (8 ml) was added Br2 (16.5 mmol) in 
48% HBr (3.2 ml).The reaction mixture was stirred at 65oC for one hour, and then stirred at 
room temperature for an additional hour. It was then quenched with ice and the solvent 
reduced under reduced pressure. Ether was added and induced precipitation. The off-white 
solid FM001 was filtered and washed with cold ether. 
 
Off-white powder (3.1 g, 68%); m.p 205 – 207oC; δH (400 MHz, DMSO): 8.71 (1H, ddd, J = 4.8, 
1.7, 0.9 Hz, H-1), 8.08 - 8.03 (1H, m, H-3), 8.00 - 7.96 (1H, m, H-4), 7.71 (1H, ddd, J = 7.5, 4.8, 1.4 
Hz,H-2), 4.97 (2H, s, H-5); δC(100  MHz, DMSO): 149.92, 149.16, 138.97, 129.47, 128.77, 124.40, 
65.62; LRMS (EI+): m/z = 198.96 (39.2 %) [M+] calculated for C7H6BrNO 198.96 [M
+].  
5.2.2. General procedure for the synthesis of 4-(pyridin-2-yl) thiazol-2-amine (FM002)  
To a solution of FM001 (11.2 mmol) in 25 ml of ethanol at room temperature  was added 
thiourea (13.4 mmol).The reaction mixture was stirred at room temperature for 1 hour, 
quenched with water and washed with dichloromethane. The aqueous phase was concentrated 
in vacuo to give a yellow solid HBr salt. The salt was then dissolved in minimal amount of water 
and 10% NaOH added drop wise until a white precipitate FM002 formed (approximately at pH 
8).The precipitate was then filtered and dried. 
 
Pink powder (1.3 g, 67%); m.p 164 – 166oC; δH (400 MHz, DMSO): 8.54 (1H, ddd, J = 3.1, 1.5, 1.0 
Hz, H-1), 7.87 – 7.77 (2H, m, H-3, 4), 7.29 – 7.20 (2H, m, H-2, 5), 7.08 (2H, s, NH2); δC (100 MHz, 
DMSO): 168.88, 152.94, 150.62, 149.70, 137.45, 122.70, 120.58, 105.85; LRMS (EI+): m/z = 













5.2.3. General procedure for the synthesis of 4-R-N-[4-(2-pyridinyl)-2-thiazolyl] – benzamides 
EDCI (1.7 mmol) was added in small batches to a solution of the carboxylic acid (1.4 mmol) and 
HOBt (1.7 mmol) in dry DCM or DMF (5 ml), and the reaction mixture was stirred for 10 minutes 
at room temperature. A solution of the amine (1.1 mmol) in 5 ml of dry DCM or DMF was added 
in small portions and the reaction mixture left to stir for 24 hr at room temperature (monitored 
by TLC until completion). The reaction mixture was then washed with saturated aqueous 
sodium bicarbonate (3 x 10ml), saturated aqueous sodium chloride (2 x 10ml), dried with 
anhydrous Na2SO4 and concentrated under reduced pressure. Purification by column silica gel 
chromatography (EtOAc/Hexane, 40:60) afforded the products as solids. 
1. 4-bromo-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 003) 
 
Pale-yellow crystals (83.5 mg, 41%); m.p 182 – 184oC; δH (400 MHz, DMSO): 12.87 (1H, s, NH), 
8.62 (1H, ddd, J = 4.8, 1.8, 1.0 Hz, H-1), 8.07 (2H, d, J = 8.6 Hz, H-6), 8.02 (1H, dt, J = 7.8, 1.0 Hz, 
H-4), 7.90 (1H, s, H-5), 7.89 (1H, td, J = 7.8, 1.8 Hz, H-3), 7.78 (2H, d, J = 8.6 Hz, H-7), 7.35 (1H, 
ddd, J = 7.8, 4.8, 1.0 Hz, H-2); δC (100 MHz, DMSO): 165.03, 159.30, 152.53,  150.01 (2C), 
137.74(2C), 132.10 (2C), 131.71, 130.75 (2C), 127.05, 120.55, 112.72; LRMS (EI+): m/z = 360.98 
(48.9%) [M+] calculated for C15H10BrN3OS 360.97 [M
+]; HPLC Purity: 99% (tr = 14.87 min). 
2. 4-iodo-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 004) 
  
Pale-yellow crystals (94.6 mg, 42%); m.p 200 – 202oC; δH (400 MHz, DMSO): 12.85 (1H, s, NH), 
8.62 (1H, ddd, J = 4.8, 1.8, 1.0 Hz, H-1), 8.02 (1H, dt, J = 7.7, 1.0 Hz, H-4), 7.97 – 7.94 (2H, m, H-
6), 7.93 – 7.88 (4H, m, H-3, 5, 7), 7.35 (IH, ddd, J = 7.7, 4.8, 1.0 Hz, H-2);  δC  (100 MHz, DMSO): 












120.55, 112.72, 100.25; LRMS (EI+): m/z = 406.95 (63.6%) [M+] calculated for C15H10IN3OS 
406.96 [M+]; HPLC Purity: 99% (tr = 15.24 min). 
3. 4-methylsulfonyl-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide(RIZ006)   
 
Off-white crystals (34.3 mg, 32%); m.p 275 – 277oC; δH (400 MHz, DMSO): 13.05 (1H, s, NH), 
8.61 (1H, ddd, J = 4.8, 1.8, 1.0 Hz, H-1), 8.33 (2H, d, J = 8.7 Hz, H-7), 8.09 (2H, d, J = 8.7 Hz, H-6), 
8.01 (1H, dt, J = 7.8, 1.0 Hz, H-4), 7.92 (1H, s, H-5), 7.89 (1H, td, J = 7.8, 1.8 Hz, H-3) 7.34 (1H, 
ddd, J = 7.8, 4.8, 1.0 Hz, H-2), 3.30 (3H, s, H-8); δC (100 MHz, DMSO ): 164.74, 159.03, 152.47, 
150.04, 144.48, 137.78, 137.00, 129.73 (2C), 127.60(2C), 123.40, 120.58, 112.93, 43.68; LRMS 
(EI+): m/z = 358.93 (77.6%) [M+] calculated for C16H13N3O3S2 359.04 [M
+]; HPLC Purity: 99% (tr = 
8.45 min). 
4. 4-acetyl-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 007) 
 
Pale-brown crystals (139.6 mg, 38%); m.p 162 – 163oC; δH (400 MHz, DMSO): 13.00 (1H, s, NH), 
8.65 (1H, ddd, J = 4.7, 1.7, 0.9 Hz, H-1), 8.27 (2H, d, J = 8.3 Hz, H-6), 8.12 (2H, d, J = 8.3 Hz, H-7), 
8.05 (1H, m, H-4), 7.97 – 7.89 (2H, m, H-3,5), 7.37 (1H, ddd, J = 7.2, 4.7, 0.9 Hz, H-2), 2.68 (3H, s, 
H-8); δC (100 MHz, DMSO ): 198.15, 165.14, 152.50, 150.01, 149.56, 140.07, 137.77, 129.05 
(2C), 128.70 (2C), 123.37, 122.77, 120.58, 112.84, 105.99, 27.49; LRMS (EI+): m/z = 323.00 
(41.8%) [M+] calculated for C17H13N3O2S 323.07 [M
















5. 4-cyano-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 008) 
 
Dark-brown crystals (151.5 mg, 44%); m.p 220 – 221oC; δH (400 MHz, DMSO): 13.02 (1H, s, NH), 
8.60 (1H, ddd, J = 4.8, 1.8, 1.1 Hz, H-1), 8.24 (2H, d, J = 8.2 Hz, H-6), 8.05 – 7.97 (3H, m, H-4, 7) 
7.92 (1H, s, H-5), 7.89 (1H, td, J = 7.6, 1.8 Hz, H-3), 7.33 (1H, ddd, J = 7.6, 4.8, 1.1 Hz, H-2); δC 
(100 MHz, DMSO ): 164.63, 152.44, 150.03, 137.78, 136.55, 133.02 (2C), 129.49 (2C), 122.72, 
120.58, 118.61, 115.25, 112.95, 105.90, 72.47; LRMS (EI+): m/z = 305.98 (92.3%) [M+] 
calculated for C16H10N4OS 306.06 [M
+]; HPLC Purity: 99% (tr = 13.13 min). 
6. 4-nitro-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 009) 
 
Deep-yellow crystals (66.6 mg, 18%); m.p 238 – 239oC; δH (400 MHz, DMSO): 13.15 (1H, s, NH), 
8.63 (1H, ddd, J = 4.8, 1.3, 1.3 Hz, H-1), 8.42 – 8.31 (2H, m, H-6, 7), 8.03 (1H, dt, J = 7.8, 1.3, Hz, 
H-4), 7.95 (1H, s, H-5), 7.91 (1H, td, J = 7.8 1.3 Hz, H-3), 7.36 (1H, ddd, J = 7.8, 4.8, 1.3 Hz, H-2); 
δC (100 MHz, DMSO): 164.40, 158.93, 152.43, 150.20, 150.05, 138.17, 137.79, 130.28 (2C), 
124.07 (2C), 123.42, 120.57, 113.00; LRMS (EI+): m/z = 325.95 (100.0%) [M+] calculated for 
C15H10N4O3S 326.05 [M
+]; HPLC Purity: 99% (tr = 13.80 min). 
7. 4-trifluoromethyl-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 010) 
 
White crystals (111.6 mg, 28%); m.p 225 – 227oC; δH (400 MHz, DMSO): 13.05 (1H, s, NH), 8.63 
(1H, ddd, J = 4.8, 1.7, 0.8 Hz, H-1), 8.32 (2H, d, J = 8.3 Hz, H-6), 8.03 (1H, m, H-4), 7.96 – 7.87 












137.76, 136.34, 132.83, 132.51, 129.64 (4C), 126.04, 123.38, 120.57, 112.89; LRMS (EI+): m/z = 
349.04 (77.4%) [M+] calculated for C16H10F3N3OS 349.05 [M
+]; HPLC Purity: 99% (tr = 14.91 min). 
8. 4-trifluoromethoxy-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 011) 
 
Brown crystals (109.5 mg, 27%); m.p 176 – 177oC; δH (400 MHz, DMSO): 12.91 (1H, s, NH), 8.62 
(1H, ddd, J = 4.8, 1.8, 1.1 Hz, H-1), 8.27 (1H, d, J = 8.4 Hz, H-6), 8.03 (1H, dt, J = 7.7, 1.1, Hz, H-4), 
7.92 (1H, s, H-5), 7.90 (1H, td, J =  7.7, 1.8 Hz, H-3) 7.55 (2H, d, J = 8.4 Hz, H-7), 7.35 (1H, ddd, J = 
7.7, 4.8, 1.1 Hz, H-2); δC (100 MHz, DMSO): 164.64, 159.14, 152.51, 151.68, 150.01, 149.89, 
137.75, 131.55, 131.19 (2C), 123.35, 121.17 (2C), 120.57, 112.76; LRMS (EI+): m/z = 365.04 
(72.6%) [M+] calculated for C16H10F3N3O2S 365.04 [M
+]; HPLC Purity: 99% (tr = 15.15 min). 
9. 4-ethyl-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 012) 
 
Pale-yellow crystals (100.5 mg, 29%); m.p 168 – 170oC; δH (400 MHz, DMSO): 12.70 (1H, s, NH), 
8.62 (1H, m, H-1), 8.08 (2H, d, J = 8.2 Hz, H-6), 8.03 (1H, d, J = 7.7 Hz, H-4), 7.90 (1H, td, J = 7.7, 
1.6 Hz, H-3), 7.89 (1H, s, H-5) 7.39 (1H, d, J = 8.2 Hz, H-7), 7.34 (1H, m, H-2), 2.70 (2H, q, J = 7.5 
Hz, H-8), 1.22 (3H, t, J = 7.5 Hz, H-9); δC (100 MHz, DMSO): 165.66, 159.35, 152.61, 149.99, 
149.84, 149.46, 137.72, 129.88, 128.81 (2C), 128.45 (2C), 123.29, 120.56, 112.52, 28.59, 15.61 ; 
LRMS (EI+): m/z = 309.07 (72.6%) [M+] calculated for C17H15F3N3OS 309.09 [M
+]; HPLC Purity: 
















10. 4-butyl-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 013) 
 
Off-white crystals (199.7 mg, 52%); m.p 93 – 95oC; δH (400 MHz, DMSO): 12.66 (1H, s, NH), 8.60 
(1H, ddd, J = 4.8, 1.8, 1.0  Hz, H-1), 8.05 (2H, d, J = 8.3 Hz, H-6), 8.01 (1H, dt, J = 7.9, 1.0  Hz, H-4), 
7.91 – 7.81 (2H, m, H-3, 5), 7.37 – 7.27 (2H, m, H-2, 7), 2.65 (2H, t, J = 7.4 Hz, H-8), 1.57 (2H, q, J 
= 7.4, Hz, H-9) 1.30 (2H, m, H-10) 0.89 (3H, t, J = 7.4 Hz, H-11) ; δC (100 MHz, DMSO): 165.67, 
159.36, 152.61, 149.99, 149.83, 148.11, 137.72, 129.87, 128.96(2C), 128.74(2C), 123.29, 120.56, 
112.51, 35.19, 33.17,  22.21, 14.19; LRMS (EI+): m/z = 337.03 (36.4%) [M+] calculated for 
C19H19F3N3OS 337.12 [M
+]; HPLC Purity: 97% (tr = 11.98 min). 
11. 4-methylthio-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 015) 
 
Pale-yellow crystals (133.3 mg, 36%); m.p 198 – 200oC; δH (400 MHz, DMSO): 12.60 (1H, s, NH), 
8.62 (1H, ddd, J = 4.8, 1.7, 1.0 Hz, H-1), 8.09 (2H, d, J = 8.5 Hz, H-6), 8.03 (1H, d, J = 7.7 Hz, H-4), 
7.94 – 7.85 (2H, m, H-3, 5), 7.41 (2H, d, J = 8.5 Hz, H-7), 7.34 (1H, ddd, J = 7.7, 4.8, 1.2  Hz, H-2), 
2.56 (3H, s, H-8); δC (100 MHz, DMSO): 165.25, 159.38, 152.61, 150.00, 149.83, 145.20, 137.72, 
129.11 (2C), 128.30, 125.40 (2C), 123.29, 120.55, 112.55, 14.50; LRMS (EI+): m/z = 326.98 
(25.3%) [M+] calculated for C16H13N3OS2 327.05 [M
+]; HPLC Purity: 99% (tr = 14.32 min). 
12. 4-chloro-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 017) 
 
Light-yellow crystals (92.7 mg, 26%); m.p 195 - 197oC; δH (400 MHz, DMSO): 12.85 (1H, s, NH), 












H-3,5), 7.61 (2H, d, J = 8.5 Hz, H-7), 7.32 (1H, m, H-2); δC (100 MHz, DMSO): 164.87, 159.15, 
152.51, 150.00, 149.87, 138.04, 137.76, 131.29, 130.61 (2C), 129.17 (2C), 123.35, 120.57, 
112.74; LRMS (EI+): m/z = 315.02 (51.4%) [M+] calculated for C15H10ClN3OS 315.02 [M
+]; HPLC 
Purity: 99% (tr = 14.69 min). 
13. 4-fluoro-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 018) 
 
Light-yellow crystals (69.6 mg, 21%); m.p 179 - 181oC; δH (400 MHz, DMSO): 12.79 (1H, s, NH), 
8.60 (1H, ddd, J = 4.8, 1.8, 1.1 Hz, H-1), 8.20 (2H, m, H-6), 8.00 (1H, dt, J = 7.7, 1.1, Hz, H-4), 7.92 
– 7.83 (2H, m, H-3, 5), 7.38 (2H, m,  H-7), 7.32 (1H, ddd, J = 7.7, 4.8, 1.1 Hz, H-2); δC (100 MHz, 
DMSO): 166.42, 164.76, 163.93, 159.23, 152.55, 150.01, 137.75, 131.61, 131.52, 129.01, 
123.33, 120.56, 116.21, 116.00, 112.66; LRMS (EI+): m/z = 299.03 (98.7%) [M+] calculated for 
C15H10FN3OS 299.05 [M
+]; HPLC Purity: 99% (tr = 13.74 min). 
14. N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 020) 
 
Pale-yellow crystals (204.8 mg, 64%); m.p 135 – 137oC; δH (400 MHz, DMSO): 12.79 (1H, s, NH), 
8.64 (1H, ddd, J = 4.8, 1.8, 1.0 Hz, H-1), 8.19-8.12 (2H, m, H-6), 8.05 (1H, dt, J = 7.9, 1.1 Hz, H-4), 
7.96 – 7.87 (2H, m, H-3, 5), 7.71-7.63  (1H, m, H-8), 7.62-7.54 (2H, m, H-7), 7.36 (1H, ddd, J = 
7.5, 4.8, 1.1 Hz, H-2); δC (100 MHz, DMSO): 165.82, 159.28, 152.58, 150.00, 137.74, 133.29, 
132.44, 129.72, 129.06 (2C), 128.67 (2C), 123.32, 120.57, 112.61; LRMS (EI+): m/z = 281.04 
(73.4%) [M+] calculated for C15H11N3OS 281.06 [M
















15. 2-bromo-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 021) 
 
Off-white crystals (228.7 mg, 56%); m.p 178 - 180oC; δH (400 MHz, DMSO): 12.85 (1H, s, NH), 
8.60 (1H, m, H-1), 7.94 (1H, m, H-4), 7.90 (1H, s, H-5), 7.87 (1H, td, J = 7.5, 1.7 Hz, H-3), 7.72 (1H, 
dd, J = 7.6, 1.4 Hz, H-6), 7.62 (1H, dd, J = 7.6, 1.4 Hz, H-9), 7.50 (1H, td, J = 7.6, 1.4 Hz, H-7), 7.47 
– 7.42 (1H, m, H-8), 7.32 (1H, ddd, J = 7.5, 4.8, 1.0 Hz, H-2); δC (100 MHz, DMSO): 166.42, 
158.39, 152.43, 150.01, 149.87, 137.76, 136.96, 133.31, 132.45, 129.85, 128.12, 123.38, 120.57, 
119.66, 112.68; LRMS (EI+): m/z = 360.91 (31.1%) [M+] calculated for C15H10BrN3OS 360.97 
[M+]; HPLC Purity: 99% (tr = 13.24 min). 
16. 3-bromo-N-[4-(2-pyridinyl)-2-thiazolyl]-benzamide (RIZ 022) 
 
Off-white crystals (284.9 mg, 70%); m.p 176 – 178oC; δH (400 MHz, DMSO): 12.87 (1H, s, NH), 
8.60 (1H, ddd, J = 4.8, 1.8, 1.1 Hz, H-1), 8.32 (1H, t, J = 1.8 Hz, H-9), 8.10 (1H, ddd, J = 7.9, 1.8, 
1.0 Hz, H-6), 8.00 (1H, dt, J = 7.7, 1.1 Hz, H-4), 7.91 – 7.85 (2H, m, H-3,5), 7.83 (1H, ddd, J = 7.9, 
1.8, 1.0 Hz, H-8), 7.51 (1H, t, J = 7.9 Hz, H-7), 7.33 (1H, ddd, J = 7.7, 4.8, 1.1 Hz, H-2); δC (100 
MHz, DMSO): 164.41, 159.05, 152.51, 150.01, 149.89, 137.75, 135.75, 134.66, 131.33, 131.24, 
127.78, 123.36, 122.30, 120.55, 112.80; LRMS (EI+): m/z = 360.87 (49.1%) [M+] calculated for 
C15H10BrN3OS 360.97 [M
+]; HPLC Purity: 99% (tr = 14.93 min). 













Off-white crystals (197.1 mg, 62%); m.p 148 – 150oC; δH (400 MHz, DMSO): 11.99 (1H, s, NH), 
8.75 (1H, ddd, J = 4.7, 1.6, 1.0 Hz, H-9), 8.59 (1H, ddd, J = 4.8, 1.7, 1.0 Hz, H-1), 8.18 (1H, dd, J = 
7.7, 1.0 Hz H-4), 8.08 (1H, td, J = 7.7, 1.6 Hz, H-7), 8.01 (1H, d, J = 7.7 Hz, H-6), 7.92 (1H, s, H-5), 
7.87 (1H, td, J = 7.7, 1.7 Hz, H-3), 7.70 (1H, ddd, J = 7.7, 4.8, 1.0 Hz, H-2), 7.31 (1H, ddd, J = 7.7, 
4.7, 1.0 Hz, H-8); δC (100 MHz, DMSO): 163.31, 157.93, 152.38, 150.02, 149.96, 149.45, 148.27, 
138.74, 137.72, 128.24, 123.40 (2C), 120.74, 112.95; LRMS (EI+): m/z = 281.94 (68.0%) [M+] 
calculated for C14H10N4OS 282.06 [M
+]; HPLC Purity: 99% (tr = 13.19 min) 
18. N-[4-(2-pyridinyl)-2-thiazolyl]-nicotinamide (RIZ 024) 
 
Off-white crystals (17.2 mg, 5%); m.p 232 – 234oC; δH (400 MHz, DMSO): 13.00 (1H, s, NH), 9.2 
(1H, m, H-6), 8.79 (1H, dd, J = 4.7, 1.4 Hz, H-7), 8.61 (1H, dd, J = 4.5, 1.2 Hz, H-1) 8.44 (1H, m, H-
9), 8.01 (1H, m, H-4), 7.92 – 7.84 (2H, m, H-3,5), 7.58 (1H, dd, J = 7.4, 4.7 Hz, H-8), 7.33 (1H, m, 
H-2); δC (100 MHz, DMSO): 164.58, 158.98, 153.42, 152.48, 150.03, 149.89, 149.66, 137.78, 
136.38, 128.47, 124.05, 123.39, 120.57, 112.83; LRMS (EI+): m/z = 282.04 (88.2%) [M+] 
calculated for C14H10N4OS 282.06 [M
+]; HPLC Purity: 99% (tr = 11.75 min). 
19. N-[4-(2-pyridinyl)-2-thiazolyl]-isonicotinamide (RIZ 025) 
 
Off-white crystals (68.6 mg, 22%); m.p 215 – 217oC; δH (400 MHz, DMSO): 13.09 (1H, s, NH), 
8.80 (2H, dd, J = 4.5, 1.7 Hz, H-7), 8.60 (1H, m, H-1), 8.04-7.96 (2H, m, H-4, 6), 7.92 (1H, s, H-5), 
7.88 (1H, td, J = 7.7, 1.8 Hz, H-3), 7.32 (1H, ddd, J = 7.7, 4.7, 1.1 Hz, H-2); δC (100 MHz, DMSO): 
164.54, 158.87, 152.43, 150.88 (2C), 150.03, 149.95, 139.64, 137.78, 123.41, 122.26 (2C), 
120.59, 113.03; LRMS (EI+): m/z = 282.01 (100.0%) [M+] calculated for C14H10N4OS 282.06 [M
+]; 













20. N-(4-(2-pyridinyl)thiazol-2-yl)thiazole-2-carboxamide (RIZ 038) 
                                                              
Off-white crystals (55.9 mg, 17%); m.p 203 – 205oC; δH (400 MHz, DMSO): 12.21 (1H, s, NH), 
9.28 (1H, d, J = 1.9 Hz, H-7), 8.74 (1H, d, J = 1.9 Hz, H-6), 8.6 (1H, ddd, J = 4.7, 1.7, 1.0 Hz, H-1), 
8.01 (1H, dd, J = 7.6, 1.0 Hz, H-4), 7.93 – 7.83 (2H, m, H-3, 5), 7.33 (1H, ddd, J = 7.6, 4.7, 1.0 Hz, 
H-2); δC
 (100 MHz, DMSO): 170.76, 159.60, 158.22, 156.04, 152.47, 149.98, 148.86, 137.72, 
127.68, 123.36, 120.66, 112.85; LRMS (EI+): m/z = 287.90 (100.0%) [M+] calculated for 
C12H8N4OS2 288.01 [M
+]; HPLC Purity: 99% (tr = 9.00 min). 
21. N-(4-(2-pyridinyl)thiazol-2-yl)-1H-imidazole-5-carboxamide (RIZ 039) 
                                                  
Pale-yellow crystals (37.7 mg, 12%); m.p 229 – 231oC; δH (400 MHz, DMSO): 12.72 (1H, s, NH), 
11.54 (1H, s, H-8), 8.59 (1H, m, H-1), 8.07 (1H, s, H-6), 7.99 (1H, d, J = 7.8 Hz, H-7) 7.91– 7.76 
(3H, m, H-3, 4, 5) 7.31 (1H, m, H-2); δC (100 MHz, DMSO): 160.89, 158.43, 152.55, 149.95, 
149.69, 137.69, 137.43,128.67, 123.27, 122.32, 120.61, 112.25; LRMS (EI+): m/z = 270.77 
(63.2%) [M+] calculated for C12H9N5OS 271.05 [M
+]; HPLC Purity: 99% (tr = 7.40 min). 
22. N-(4-(2-pyridinyl)thiazol-2-yl)thiophene-2-carboxamide (RIZ 042) 
                                                                 
Pale-brown crystals (73.3 mg, 23%); m.p 163 – 165oC; δH (400 MHz, DMSO): 12.86 (1H, s, NH), 
8.60 (1H, ddd, J = 4.8, 1.3, 0.9 Hz, H-1), 8.29 (1H, dd, J = 3.8, 1.1 Hz, H-8), 8.00 (1H, dt, J = 7.7, 
1.3 Hz, H-4), 7.96 (1H, dd, J = 5.0, 1.1 Hz, H-7), 7.91 – 7.85 (2H, m, H-3,5), 7.32 (1H, ddd, J = 7.7, 












152.53, 150.01, 149.87, 137.73, 137.59, 134.17, 131.45, 129.05, 123.32, 120.54, 112.70; LRMS 
(EI+): m/z = 287.00 (58.5%) [M+] calculated for C13H9N3OS2 287.02 [M
+]; HPLC Purity: 99% (tr = 
9.43 min). 
23. N-4-bromo-N-[4-(3-pyridinyl)-2-thiazolyl]-benzamide (RIZ 034) 
 
White crystals (79.0 mg, 20%); m.p 233 – 235oC;  δH  (400 MHz, DMSO): 12.87 (1H, s, NH), 9.29-
8.94 (1H, m, H-1), 8.52 (1H, dd, J = 4.7, 1.7 Hz, H-2), 8.26 (1H, dt, J = 8.0, 1.7  Hz, H-4), 8.05 (1H, 
d, J  = 8.6 Hz, H-7), 7.86 (1H, S, H-5), 7.76 (1H, d, J = 8.6 Hz, H-6), 7.50-7.42 (1H, m, H-3); δC (100 
MHz, DMSO): 165.02, 159.44, 149.18, 147.52, 147.34, 133.40, 132.12 (2C), 131.62, 130.76 (2C), 
130.45, 127.10, 124.29, 110.72 ;  LRMS (EI+): m/z = 360.87 (38.0%) [M+] calculated for 
C15H10BrN3OS 360.97 [M
+]; HPLC Purity: 95% (tr = 10.44 min). 
24. N-4-bromo-N-[4-(4-pyridinyl)-2-thiazolyl]-benzamide (RIZ 035) 
 
Off-white crystals (93.5 mg, 23%);  m.p  251 – 253oC; δH  (400 MHz, DMSO): 12.88 (1H, s, NH), 
8.62 (2H, dd, J = 4.5, 1.6 Hz, H-1), 8.07-8.02 (3H, m,  H-3, 5), 7.87 (1H, dd, J  = 4.5, 1.6  Hz, H-2), 
7.77-7.74 (2H,  m,  H-4);  δC (100 MHz, DMSO): 165.12, 159.45, 150.75 (2C), 147.21, 141.45, 
132.12 (2C),  130.77 (2C), 127.14, 120.50 (2C), 113.33; LRMS (EI+): m/z = 360.86 (32.6%) [M+] 
calculated for C15H10BrN3OS 360.97 [M
+]; HPLC Purity: 99% (tr = 10.18 min). 
5.3. General procedure for the synthesis of N-phenyl-[4-(2-pyridinyl) thiazole-2-amine (RIZ 
020B) 
A mixture of FM001 (1.78 mmol) and phenylthiourea (1.78 mmol) in 10 ml of ethanol was 
refluxed for 1 hr, the mixture was then cooled to 20oC and diluted with 25 ml of water. The pH 












stirred for 2 hr at 20oC and a precipitate formed. The precipitate was filtered and washed with 5 
ml of water and dried. Purification was done via column chromatography: EtOAc: Hexane 
(30:70) 
 
Brown crystals (264.2 mg, 59%); m.p 142 – 144oC; δH (400 MHz, DMSO): 10.27 (1H, s, NH), 8.64-
8.49 (1H, m, H-1), 7.99 (1H, d, J = 7.7 Hz, H-4), 7.88 (1H, td, J = 7.7, 1.8  Hz, H-3), 7.72 (2H, d, J  = 
7.6 Hz, H-6), 7.53 (1H, s, H-5), 7.38 – 7.27 (3H, m, H-2,7), 6.96 (1H, t, J = 7.4, H-8); δC (100 MHz, 
DMSO): 163.90, 152.57, 150.76, 149.78, 141.62, 137.80, 129.49 (2C) ,123.10, 121.79, 120.87, 
117.40 (2C), 107.30; LRMS (EI+): m/z = 252.78 (100%) [M+] calculated for C14H11N3S 253.07 
[M+]; HPLC Purity: 98% (tr = 7.66 min). 
5.4. General procedure for the synthesis of 1-phenyl-3-[4-(2-pyridinyl) thiazol-2-yl) urea 
(RIZ 020C) 
A mixture of aniline (2.15 mmol) and triphosgene (2.15 mmol) in 10 ml of toluene was refluxed 
for 8 hr to generate the phenylisocyanate in situ; the mixture was then cooled to 0oC using ice 
and the amine FM002 (2.15 mmol) added. The mixture was then warmed to 56oC and left to stir 
at this temperature for 2 hr, the heat was then turned off and the mixture left to stir at room 
temperature for 24 hr. Overnight a precipitate formed. The precipitate was filtered and 
recrystallized from absolute ethanol to yield the desired product. 
 
Pale-brown crystals (172.0 mg, 27%); m.p 215 – 217oC; δH (400 MHz, DMSO): 10.99 (1H, s, NH-
thiazole), 9.97 (1H, s, NH-phenyl), 8.68 (1H, m, H-1), 8.39-8.19 (3H, m, H-3, 4, 5), 7.69 (1H, m, H-
2), 7.49 (2H, d, J = 8.3 Hz,  H-6), 7.31 (2H, t, J = 7.3 Hz, H-7), 7.10-6.96 (1H, m, H-8); δC (100 MHz, 












122.97, 119.11, 119.00, 116.33; LRMS (EI+): m/z = 295.95 (13.7%) [M+] calculated for 
C15H12N4OS 296.07 [M
+]; HPLC Purity: 99% (tr = 9.42 min). 
5.5. General procedure for the synthesis of N-[4-(2-pyridinyl) thiazol-2-ylcarbamothioyl) 
benzamide (RIZ 020F) 
A solution of benzoylisothiocyanate (3.1 mmol) and FM002 (2.82 mmol) in 10 ml of acetone 
was refluxed for 3 hr. The resulting precipitate was filtered off yielding the desired product. 
 
Pale-green crystals (484.4 mg, 51%); m.p 205 – 207oC; δH (400 MHz, DMSO): 12.13 (1H, s, NH), 
8.60 (1H, ddd, J = 4.8, 1.8, 1.0 Hz, H-1), 8.05-7.97 (3H, m, H-4, 6), 7.91 (1H, s, H-5), 7.88 (1H, td, J 
= 7.6, 1.8 Hz, H-3), 7.67 (1H, m, H-8), 7.59-7.52 (2H, m, H-7), 7.34 (1H, ddd, J  =  7.6, 4.8, 1.0 
Hz,H-2); δC (100 MHz, DMSO): 176.75, 169.25, 159.19, 152.30, 150.10, 149.97, 137.65, 133.80, 
132.44, 129.24 (2C), 128.93 (2C), 123.48, 120.78, 112.76; LRMS (EI+): m/z = 339.63 (69.9%) 
[M+] calculated for C16H12N4OS2 340.05 [M
+]; HPLC Purity: 99% (tr = 11.22 min). 
5.6. Synthesis of the 4-R-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-
fg]quinolin-9-yl)methyl)benzamides 
5.6.1 Synthesis of (4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl) 
methanamine (FRM 000) 
Metergoline (1.6mmol) was dissolved in 20mls of a 1:1 mixture of EtOH and THF. 16% Pd/C was 
added, the flask purged three times with hydrogen gas, sealed under an atmosphere of 
hydrogen and stirred at room temperature for 10 hours. The reaction mixture was then filtered 
through celite, and the solvent removed under reduced pressure. The resulting residue was 
dissolved in a small volume of ethyl acetate, and the final compound precipitated out using 













Off-white powder (554.8mg, 78%); m.p 151 – 153oC;  δH(400 MHz, CDCl3): 7.22 (1H, dd, J = 8.1, 
7.1 Hz, H-11), 7.14 (1H, d, J = 8.2 Hz, H-10), 6.96 (1H, d, J =7.1 Hz, H-12), 6.75 (1H, d, J = 1.5 Hz, 
H-2), 3.78 (3H, s, H-1), 3.42 (1H, dd, J = 14.7, 4.3 Hz, H-4), 3.16 (1H, dd, J = 7.6, 2.0 Hz, H-9), 3.07 
– 2.95 (1H, m, H-13 (H)), 2.81 – 2.63 (4H, m, H-3 (H), H-6 (H), H-8 (H), H-13 (H),), 2.52 (3H, s, H-
5), 2.18 (1H, ddd, J = 11.0, 9.7, 4.4 Hz, H-3 (H)), 2.10 – 1.92 (2H, m, H- 6 (H), H-8 (H)), 1.75 (2H, s, 
NH2), 1.14 (1H, q, J = 12.2 Hz, H-7); δC(100 MHz, CDCl3): 134.57, 133.67, 126.66, 122.71, 122.38, 
112.57, 110.94, 106.64, 67.67, 61.83, 46.59, 43.19, 40.57, 39.26, 32.61, 32.25, 27.00; LRMS 
(EI+): m/z = 269.15 (100.0%) [M+] calculated for C17H23N3 269.19 [M
+]; HPLC Purity: 99% (tr = 
4.75 min). 
5.6.2 Synthesis of the 4-R-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-
fg]quinolin-9-yl)methyl)benzamides. 
EDCI (1.5 mmol) was added in small batches to a solution of the carboxylic acid (1.2 mmol) and 
HOBt (1.5 mmol) in 5 ml dry DCM. The reaction mixture was stirred for 10 minutes at room 
temperature, then a solution of the amine (1.0 mmol) in 5 ml of dry DCM was added in small 
portions and the reaction mixture left to stir for 24 hr at room temperature (monitored by TLC 
until completion). The reaction mixture was washed with saturated aqueous sodium 
bicarbonate (2 x 10ml), saturated aqueous sodium chloride (1 x 10ml), dried with anhydrous 
Na2SO4 and concentrated under reduced pressure. Purification by column silica gel 

















yl)methyl)benzamide (FRM 001) 
 
Off-white powder (45.2 mg, 53%); m.p 213 – 215oC; δH(400 MHz, CDCl3): 7.75 (2H, d, J = 8.3 Hz, 
H-14), 7.52 (2H, d, J = 8.3 Hz, H-15), 7.18 – 7.11 (2H, m, H-11, NH), 7.09 (1H, d, J = 7.9 Hz, H-10), 
6.83 (1H, d, J = 7.4 Hz, H-12), 6.71 (1H, s, H-2), 3.71 (3H, s, H-1), 3.67 (2H, q, J = 7.0 Hz), 3.56 – 
3.43 (1H, m), 3.38 (2H, dd, J = 14.8, 4.3 Hz), 3.33 – 3.22 (1H, m), 3.06 – 2.92 (1H, m), 2.66 (3H, s, 
H-5), 2.63 – 2.52 (1H, m), 2.38 – 2.28 (1H, m), 1.20 (1H, dd, J = 13.4, 6.4 Hz), 0.86 (1H, d, J = 6.2 
Hz); δC(100 MHz, CDCl3): 167.03, 134.43, 133.12, 131.19 (2C), 131.12, 128.92 (2C), 126.19, 
126.09, 124.98, 122.94, 112.89, 108.66, 107.42, 67.48, 60.62, 43.35, 42.06, 39.38, 35.12, 33.44, 
32.83, 26.74; LRMS (EI+): m/z = 450.98 (100.0%) [M+] calculated for C24H26BrN3O 451.13 [M
+]; 
HPLC Purity: 99% (tr = 13.33 min). 
2. 4-ethyl-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-
yl)methyl)benzamide (FRM 002) 
 
Pale brown powder (49.1mg, 37%); m.p 192 – 194oC; δH(400 MHz, CDCl3): 7.72 (2H, d, J = 8.1 
Hz, H-14), 7.21 (2H, d, J = 7.6 Hz, H-15), 7.17 – 7.10 (1H, m, H-11), 7.07 (1H, d, J = 8.1 Hz, H-10), 
6.83 (1H, d, J = 7.0 Hz, H-12), 6.69 (1H, s, H-2), 6.65 – 6.58 (1H, m, NH), 3.70 (5H, m,), 3.54 – 
3.29 (4H, m), 3.24 (1H, d, J = 10.9 Hz), 3.19 – 3.08 (1H, m), 2.90 – 2.77 (1H, m), 2.73 – 2.59 (3H, 
m), 2.54 (3H, s, H-5), 2.44 – 2.25 (2H, m), 2.20 (1H, m,), 1.21 (1H, q, J = 7.9 Hz); δC(100 MHz, 
CDCl3): 167.83, 148.17, 134.43, 132.19, 131.86, 128.07 (2C), 127.50 (2C), 126.29, 122.81, 












26.25, 15.28; LRMS (EI+): m/z = 401.07 (100.0%) [M+] calculated for C26H31N3O 401.25 [M
+]; 
HPLC Purity: 98% (tr = 13.39 min). 
3. 4-cyano-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-
yl)methyl)benzamide (FRM 003) 
 
Brown powder (68.7mg,52.2%); m.p 137 – 139oC; δH(400 MHz, CDCl3): 8.00 (2H, d, J = 8.2 Hz, H-
14), 7.66 (2H, d, J = 8.1 Hz, H-15), 7.30 (1H, m, NH), 7.18 – 7.13 (1H, m, H-11), 7.11 (1H, d, J = 8.2 
Hz, H-10), 6.84 (1H, d, J = 6.6 Hz, H-12), 6.74 (1H, s, H-2), 3.73 (3H, s, H-1), 3.59 – 3.47 (3H, m), 
3.47 – 3.36 (2H, m), 3.36 – 3.27 (1H, m), 3.02 (1H, dd, J = 13.7, 12.5 Hz), 2.69 (3H, s, H-5), 2.68 – 
2.58 (1H, m), 2.43 – 2.33 (1H, m), 1.32 (1H, q, J = 11.9 Hz), 1.24 – 1.18 (1H, m); δC(100 MHz, 
CDCl3): 166.13, 138.09, 134.45, 132.33 (2C), 131.79, 130.90, 129.91, 128.01 (2C), 126.04, 
123.04, 122.96, 112.84, 108.42, 107.57 67.57, 60.66, 43.48, 42.04, 39.42, 35.11, 32.87, 31.44, 
25.67; LRMS (EI+): m/z = 397.99 (100.0%) [M+] calculated for C25H26N4O 398.21 [M
+]; HPLC 
Purity: 95% (tr = 11.60 min). 
4. 4-nitro-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-
yl)methyl)benzamide (FRM 004) 
 
Orange powder (51.6mg,37.4%); m.p 228 – 230oC; δH(400 MHz, CDCl3): 8.21 (2H, d, J = 8.6 Hz, 
H-14), 7.95 (2H, d, J = 8.5 Hz, H-15), 7.17 – 7.11 (1H, m, H-11), 7.08 (1H, d, J = 8.1 Hz, H-10), 6.83 
(1H, d, J = 7.2 Hz), 6.79 (1H, s, NH), 6.70 (1H, s, H-2), 3.72 (3H, s, H-1), 3.48 (2H, t, J = 6.2 Hz), 
3.36 (1H, dd, J = 14.5, 4.4 Hz), 3.22 (1H, d, J = 11.0 Hz), 3.13 – 3.05 (1H, m), 2.83 – 2.67 (2H, m), 












(1H, m); δC(100 MHz, CDCl3): 165.81, 149.60, 140.02, 134.44, 132.11, 128.27 (2C), 126.28, 
123.75 (2C), 122.79 (2C), 112.61, 109.65, 107.18 67.50, 61.22, 43.90, 42.82, 40.01, 36.17, 32.78, 
31.93, 26.45; LRMS (EI+): m/z = 417.94 (100.0%) [M+] calculated for C24H26N4O 418.20 [M
+]; 
HPLC Purity: 98% (tr = 12.48 min). 
5. 4-chloro-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-
yl)methyl)benzamide (FRM 005) 
 
Off-white powder (52.5mg,34.8%); m.p 224 – 226oC; δH(400 MHz, CDCl3): 7.76 (2H, d, J = 8.3 Hz, 
H-14), 7.35 (2H, d, J = 8.4 Hz, H-15), 7.26 (1H, s, NH), 7.16 – 7.10 (1H, m, H-11), 7.07 (1H, d, J = 
8.2 Hz, H-10), 6.83 (1H, d, J = 6.9 Hz, H-12), 6.69 (1H, s, H-2), 3.70 (3H, s, H-1), 3.41 – 3.30 (3H, 
m), 3.23 (1H, d, J = 10.4 Hz), 3.10 – 3.00 (1H, m), 2.82 – 2.72 (1H, m), 2.65 (1H, d, J = 12.6 Hz), 
2.49 (3H, s, H-5), 2.27 (2H, td, J = 10.7, 4.2 Hz), 2.13 – 2.03 (1H, m), 1.27 – 1.13 (1H, m); δC(100 
MHz, CDCl3): 166.71, 137.74, 134.46, 132.95, 132.51, 128.85 (2C), 128.48 (2C), 126.39, 122.80, 
122.69 112.62, 110.01, 107.07 67.41, 61.20, 43.77, 42.83, 40.24, 36.17, 32.78, 31.97, 26.52; 
LRMS (EI+): m/z = 406.87 (100.0%) [M+] calculated for C24H26ClN3O 407.18 [M
+]; HPLC Purity: 
99% (tr = 13.19 min). 
6. 4-dimethylamino-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-
fg]quinolin-9-yl)methylbenzamide (FRM 006) 
 
Off-white powder (120.9mg,78.4%); m.p 258 – 260oC; δH(400 MHz, CDCl3): 7.66 (2H, d, J = 8.7 
Hz, H-14), 7.18 – 7.11 (1H, m, H-11), 7.07 (1H, d, J = 8.2 Hz, H-10), 6.86 (1H, d, J = 6.9 Hz, H-12), 












3.40 (3H, m), 3.34 (1H, dd, J = 14.7, 4.4 Hz), 3.07 (1H, d, J = 10.6 Hz), 2.98 (6H, s, H-16), 2.73 – 
2.61 (2H, m), 2.43 (3H, s, H-5), 2.25 – 2.17 (1H, m), 2.18 – 2.10 (1H, m), 2.07 – 1.98 (1H, m), 1.24 
– 1.13 (1H, m); δC(100 MHz, CDCl3): 167.59, 152.52, 134.45, 133.29, 128.35 (2C), 126.53, 
122.73, 122.49, 121.51 112.60, 111.18 (2C), 110.69, 106.79 67.45, 61.60, 43.57, 43.28, 40.58, 
40.12, 36.97, 32.74, 32.22, 26.95, 15.26; LRMS (EI+): m/z  = 415.92 (63.0%) [M+] calculated for 
C26H32N4O 416.26 [M
+]; HPLC Purity: 99% (tr = 12.54 min). 
7. 4-butyl-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-
yl)methyl)benzamide (FRM 007) 
 
Dark brown powder (60.4mg,38.0%); m.p 171 – 173oC; δH(400 MHz, CDCl3): 7.70 (2H, d, J = 8.0 
Hz, H-14), 7.21 (2H, d, J = 7.8 Hz, H-15), 7.18 – 7.11 (1H, m, H-11), 7.07 (1H, d, J = 7.9 Hz, H-10), 
6.86 (1H, d, J = 6.9 Hz, H-12), 6.69 (1H, s, H-2), 6.39 – 6.31 (1H, m, NH), 3.71 (3H, s, H-1), 3.52 – 
3.40 (2H, m), 3.40 – 3.31 (1H, m), 3.18 (1H, dd, J = 10.6, 1.7 Hz), 3.11 – 3.00 (1H, m), 2.80 – 2.65 
(2H, m), 2.65 – 2.59 (2H, m), 2.48 (3H, s, H-5), 2.24 (1H, td, J = 11.2, 4.6 Hz), 2.08 (1H, t, J = 11.4 
Hz), 1.58 (2H, p, J = 7.8 Hz), 1.36 – 1.29 (2H, m), 1.25 – 1.20 (2H, m), 0.90 (3H, t, J = 7.4 Hz); 
δC(100 MHz, CDCl3): 167.74, 146.82, 134.45, 132.84, 132.01, 128.63 (2C), 126.98 (2C), 126.45, 
122.77, 122.60 112.63, 110.29, 106.94 67.42, 61.30, 43.65, 42.96, 40.29, 36.43, 35.63, 35.52, 
33.34, 32.06, 26.64, 22.29, 13.88; LRMS (EI+): m/z = 428.91 (100.0%) [M+] calculated for 
C28H35N3O 429.28 [M
+]; HPLC Purity: 99% (tr = 14.69 min). 
8. 4-methylthio-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-













Pale brown powder (47.6mg,30.7%); m.p 214 – 216oC; δH(400 MHz, CDCl3): 7.71 (2H, d, J = 7.9 
Hz, H-14), 7.24 (2H, d, J = 8.2 Hz, H-15), 7.18 – 7.11 (1H, m, H-11), 7.08 (1H, d, J = 7.8 Hz, H-10), 
6.86 (1H, d, J = 6.5 Hz, H-12), 6.69 (1H, s, H-2), 6.34 (1H, s, NH), 3.71 (3H, s, H-1), 3.50 – 3.39 
(2H, m), 3.36 (1H, dd, J = 14.7, 4.6 Hz), 3.18 (1H, d, J = 9.9 Hz), 3.09 – 2.98 (1H, m), 2.78 – 2.64 
(2H, m), 2.48 (3H, s, H-16), 2.47 (3H, s, H-5), 2.34 – 2.20 (2H, m), 2.08 (1H, t, J = 11.5 Hz), 1.26 – 
1.19 (1H, m); δC(100 MHz, CDCl3): 167.18, 143.40, 134.45, 132.81, 127.38 (2C), 126.44, 125.61 
(2C), 125.12, 122.77, 122.62 112.61, 110.28, 106.96 67.42, 61.33, 43.71, 40.34, 36.44, 32.76, 
32.06, 26.66, 15.14; LRMS (EI+): m/z = 418.81 (100.0%) [M+] calculated for C25H29N3OS 419.20 
[M+]; HPLC Purity: 99% (tr = 12.94 min). 
9. 4-iodo-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-
yl)methyl)benzamide (RIZ 009) 
 
Off-white powder (84.6mg,45.8%); m.p 227 – 229oC; δH(400 MHz, CDCl3): 7.80 (2H, d, J = 7.5 Hz, 
H-14), 7.60 (2H, d, J = 8.4 Hz), 7.23 – 7.15 (1H, m, H-11), 7.12 (1H, d, J = 8.0 Hz, H-10), 6.89 (1H, 
d, J = 7.3 Hz, H-12), 6.75 (1H, s, H-2), 6.65 (1H, s, NH), 3.76 (3H, s, H-1), 3.52 – 3.33 (4H, m), 3.22 
– 3.10 (1H, m), 2.93 – 2.81 (1H, m), 2.72 (1H, d, J = 13.5 Hz), 2.58 (3H, s, H-5), 2.49 – 2.34 (1H, 
m), 2.25 – 2.13 (1H, m), 1.37 – 1.24 (1H, m), 1.21 (1H, t, J = 7.0 Hz); δC(100 MHz, CDCl3): 166.99, 
137.80 (2C), 137.18, 134.46, 133.93, 132.26, 128.70 (2C), 126.34, 122.83, 122.74 112.67, 
109.76, 107.14 67.40, 61.06, 43.71, 42.64, 40.12, 35.89, 32.79, 31.87, 26.34; LRMS (EI+): m/z = 
498.98 (100.0%) [M+] calculated for C24H26IN3O 499.11 [M

















fg]quinolin-9-yl)methyl)benzamide (FRM 010) 
 
Pale brown powder (73.9mg,44.2%); m.p 209 – 211oC; δH(400 MHz, CDCl3): 8.01 – 7.93 (4H, m, 
H-14, H-15), 7.21 – 7.15 (1H, m, H-11), 7.11 (1H, d, J = 8.2 Hz, H-10), 6.88 (1H, d, J = 7.1 Hz, H-
12), 6.73 (1H, d, J = 1.2 Hz, H-2), 6.53 (1H, s, NH), 3.75 (3H, s, H-1), 3.54 – 3.46 (2H, m), 3.38 (1H, 
dd, J = 14.7, 4.3 Hz), 3.14 – 3.07 (1H, m), 3.05 (3H, s, H-16), 3.03 – 2.89 (1H, m), 2.77 – 2.64 (2H, 
m), 2.48 (3H, s, H-5), 2.33 – 2.21 (1H, m), 2.18 (1H, td, J = 10.4, 4.4 Hz), 2.06 (1H, t, J = 11.3 Hz), 
1.35 – 1.17 (1H, m); δC(100 MHz, CDCl3): 166.14, 142.95, 139.79, 134.46, 133.05, 128.10 (2C), 
127.75 (2C), 126.51, 122.71, 122.62, 112.49, 110.56, 106.93, 67.40, 61.51, 44.40, 44.10, 43.30, 
40.55, 36.68, 32.76, 32.20, 26.96; LRMS (EI+): m/z = 451.16 (100.0%) [M+] calculated for 
C25H29N3O3S 451.19 [M
+]; HPLC Purity: 99% (tr = 10.66 min). 
11. 4-methoxy-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-
yl)methyl)benzamide (FRM 011) 
 
Pale brown powder (61.8mg,41.4%); m.p 212 – 214oC; δH(400 MHz, CDCl3): 7.76 (2H, d, J = 8.8 
Hz, H-14), 7.21 – 7.15 (1H, m, H-11), 7.11 (1H, d, J = 8.2 Hz, H-10), 6.94 (2H, d, J = 8.8 Hz, H-15), 
6.90 (1H, d, J = 7.1 Hz, H-12), 6.72 (1H, d, J = 1.3 Hz, H-2), 6.18 (1H, t, J = 5.8 Hz, NH), 3.85 (3H, s, 
H-16), 3.75 (3H, s, H-1), 3.48 (2H, q, J = 7.0 Hz), 3.38 (1H, dd, J = 14.7, 4.3 Hz), 3.11 (1H, ddd, J = 
11.6, 3.3, 2.1 Hz), 3.03 – 2.95 (1H, m), 2.77 – 2.64 (2H, m), 2.47 (3H, s, H-5), 2.30 – 2.21 (1H, m), 
2.21 – 2.14 (1H, m), 2.06 (1H, t, J = 11.3 Hz), 1.21 (1H, t, J = 7.0 Hz); δC(100 MHz, CDCl3): 167.21, 












110.66, 106.83 67.43, 61.57, 55.41, 43.73, 43.29, 40.58, 36.89, 32.74, 32.21, 26.96; LRMS (EI+): 
m/z = 403.12 (100.0%) [M+] calculated for C25H29N3O2 403.23 [M
+]; HPLC Purity: 99% (tr = 12.13 
min). 
12. 4-trifluoromethyl-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-
fg]quinolin-9-yl)methyl)benzamide (FRM 012) 
 
Off-white powder (69.7mg, 43%); m.p 228 – 230oC; δH(400 MHz, CDCl3): 7.93 (2H, d, J = 8.1 Hz, 
H-14), 7.75 (2H, d, J = 8.7 Hz, H-15), 7.26 – 7.17 (1H, m, H-11), 7.15 (1H, d, J = 8.9 Hz, H-10), 6.92 
(1H, d, J = 8.1 Hz, H-12), 6.76 (1H, d, J = 1.4 Hz, H-2), 6.36 (1H, t, J = 6.0 Hz, NH), 3.79 (3H, s, H-
1), 3.54 (2H, t, J = 6.4 Hz), 3.42 (1H, dd, J = 14.7, 4.3 Hz), 3.13 (1H, ddd, J = 11.2, 3.6, 2.0 Hz), 
3.03 (1H, td, J = 12.2, 3.6 Hz), 2.74 (2H, dddd, J = 16.3, 12.7, 8.4, 2.6 Hz), 2.51 (3H, s, H-5), 2.37 – 
2.26 (1H, m), 2.25 – 2.17 (1H, m), 2.10 (1H, t, J = 11.3 Hz), 1.28 (1H, q, J = 12.3 Hz); δC(100 MHz, 
CDCl3): 166.47, 137.99, 134.46, 133.07, 127.40 (4C), 126.51, 125.71, 125.68, 122.72, 122.59, 
112.49, 110.59, 106.91, 67.41, 61.53, 43.99, 43.30, 40.56, 36.78, 32.74, 32.20, 26.97; LRMS 
(EI+): m/z = 440.94 (100.0%) [M+] calculated for C25H26F3N3O 441.20 [M
+]; HPLC Purity: 99% (tr = 
13.54 min). 
13.  4-acetyl-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-
yl)methyl)benzamide (FRM 013) 
 
Light brown powder (62.6mg,40.7%); m.p 198 – 200oC; δH(400 MHz, CDCl3): 8.01 (2H, d, J = 8.2 
Hz, H-14), 7.91 (2H, d, J = 8.3 Hz, H-15), 7.21 – 7.14 (1H, m, H-11), 7.11 (1H, d, J = 8.2 Hz, H-10), 












7.0 Hz), 3.39 (1H, dd, J = 14.7, 4.2 Hz), 3.21 (1H, d, J = 8.7 Hz), 3.11 – 3.01 (1H, m), 2.78 – 2.69 
(1H, m), 2.62 (3H, s, H-16), 2.52 (3H, s, H-5), 2.40 – 2.32 (1H, m), 2.32 – 2.22 (1H, m), 2.12 (1H, t, 
J = 11.3 Hz), 1.37 – 1.13 (1H, m); δC(100 MHz, CDCl3): 197.40, 166.82, 139.23, 138.51, 134.45, 
132.67, 128.54 (2C), 127.34 (2C), 126.42, 122.76, 122.66, 112.58, 110.17, 107.02, 67.39, 65.82, 
61.31, 43.86, 42.99, 40.32, 36.37, 32.76, 32.04, 26.76; LRMS (EI+): m/z = 414.79 (100.0%) [M+] 
calculated for C26H29N3O2 415.23 [M
+]; HPLC Purity: 99% (tr = 11.64 min). 
14. 4-fluoro-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-
yl)methyl)benzamide (FRM 014) 
 
Off-white powder (40.6mg,28.0%); m.p 212 – 214oC; δH(400 MHz, CDCl3): 7.83 – 7.77 (2H, m, H-
14), 7.21 – 7.15 (1H, m, H-11), 7.12 (3H, t, J = 8.5 Hz, H-10, H-15), 6.89 (1H, d, J = 7.1 Hz, H-12), 
6.73 (1H, d, J = 1.3 Hz, H-2), 6.27 – 6.19 (1H, m, NH), 3.75 (3H, s, H-1), 3.52 – 3.45 (2H, m), 3.39 
(1H, dd, J = 14.7, 4.4 Hz), 3.13 – 3.06 (1H, m), 3.05 – 2.93 (1H, m), 2.77 – 2.63 (2H, m), 2.47 (3H, 
s, H-5), 2.31 – 2.20 (1H, m), 2.22 – 2.13 (1H, m), 2.06 (1H, t, J = 11.3 Hz), 1.30 – 1.18 (1H, m); 
δC(100 MHz, CDCl3): 166.69, 166.00, 134.47, 133.17, 130.92, 129.27, 129.18, 126.54, 122.74, 
122.58, 115.78, 115.56 112.54, 110.66, 106.89, 67.44, 61.58, 43.91, 43.34, 40.60, 36.86, 32.76, 
32.23, 27.00; LRMS (EI+): m/z = 391.18 (100.0%) [M+] calculated for C24H26FN3O 391.21 [M
+]; 
HPLC Purity: 99% (tr = 12.33 min). 
15.  N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-













Off-white powder (37.8mg,27.4%); m.p 205 – 207oC; δH(400 MHz, CDCl3): 7.86 – 7.80 (2H, m, H-
14), 7.54 – 7.42 (3H, m, H-15, H-16), 7.22 – 7.14 (1H, m, H-11), 7.12 (1H, d, J = 8.2 Hz, H-10), 
6.90 (1H, d, J = 7.1 Hz, H-12), 6.74 (1H, s, H-2), 6.44 (1H, s, NH), 3.76 (3H, s, H-1), 3.54 – 3.48 
(2H, m), 3.41 (1H, dd, J = 14.7, 4.3 Hz), 3.26 (1H, d, J = 12.1 Hz), 3.15 – 3.06 (1H, m), 2.84 – 2.70 
(2H, m), 2.54 (3H, s, H-5), 2.30 (1H, td, J = 10.8, 4.7 Hz), 2.14 (1H, t, J = 11.4 Hz), 1.34 – 1.19 (2H, 
m); δC(100 MHz, CDCl3): 167.77, 134.65, 132.75, 131.46, 128.61 (2C), 127.94, 126.98 (2C), 
126.43, 122.78, 122.63, 112.63, 110.21, 106.98, 67.41, 61.27, 43.71, 42.92, 40.27, 36.34, 32.77, 
32.04, 26.59; LRMS (EI+): m/z = 373.13 (100.0%) [M+] calculated for C24H27N3O 373.22 [M
+]; 
HPLC Purity: 99% (tr = 11.95 min). 
16. 4-trifluoromethoxy-N-((4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-
fg]quinolin-9-yl)methyl)benzamide (FRM 016) 
 
Brown powder (38.8mg,22.9%); m.p 182 – 184oC; δH(400 MHz, CDCl3): 7.84 (2H, d, J = 8.9 Hz, H-
14), 7.29 (2H, d, J = 8.9 Hz, H-15), 7.21 – 7.15 (1H, m, H-11), 7.11 (1H, d, J = 8.2 Hz, H-10), 6.89 
(1H, d, J = 6.2 Hz, H-12), 6.73 (1H, d, J = 1.4 Hz, H-2), 6.27 – 6.19 (1H, m, NH), 3.75 (3H, s, H-1), 
3.49 (2H, t, J = 6.4 Hz), 3.39 (1H, dd, J = 14.6, 4.4 Hz), 3.13 – 3.07 (1H, m), 3.03 – 2.95 (1H, m), 
2.77 – 2.65 (2H, m), 2.48 (3H, s, H-5), 2.27 (1H, dd, J = 12.0, 7.0 Hz), 2.23 – 2.14 (1H, m), 2.07 
(1H, t, J = 11.3 Hz), 1.25 (1H, q, J = 12.4 Hz); δC(100 MHz, CDCl3): 166.40, 151.49, 134.45, 133.13, 
128.77 (2C), 126.50, 122.64, 120.72 (2C), 112.50, 110.59, 106.89, 67.42, 61.53, 43.93, 43.29, 
40.56, 36.80, 32.75, 32.19, 26.96; LRMS (EI+): m/z  =  457.15 (100.0%) [M+] calculated for 
C25H26F3N3O2 457.20 [M
+]; HPLC Purity: 99% (tr = 13.84 min). 
5.7. Synthesis of the N-(4-chlorobenzyl)-1-(4,7-dimethyl-4,6,6a,7,8,9,10,10a-octahydroindolo 
[4,3-fg]quinolin-9-yl)methanamine (FRM 017) 
A mixture of the amine FRM000 (1.0 mmol) and 4-chloro benzaldehyde (1.0 mmol) in 5 ml of 












then cooled to 0oC using ice and sodium borohydride (2.0 mmol) added. The mixture was then 
warmed to room temperature and left to stir for 24 hr. The reaction was then quenched with 
water and extracted with DCM. The DCM layer was the concentrated in vacuo to give the crude 
product that was purified by column silica gel chromatography (MeOH/DCM, 5:95) to yield the 
desired product. 
 
Brown powder (51.5mg,35%); m.p 56 – 58oC; δH(400 MHz, CDCl3): 7.37 – 7.31 (4H, m, H-15, H-
16), 7.22 (1H, dd, J = 8.2, 7.1 Hz, H-11), 7.14 (1H, d, J = 8.2 Hz, H-10), 6.94 (1H, d, J = 6.8 Hz, H-
12), 6.76 (1H, d, J = 1.5 Hz, H-2), 3.84 (2H, d, J = 3.1 Hz, H-14), 3.78 (3H, s, H-1), 3.42 (1H, dd, J = 
14.7, 4.3 Hz), 3.20 (1H, ddd, J = 11.1, 3.6, 1.8 Hz), 3.03 (1H, td, J = 12.3, 3.9 Hz), 2.82 – 2.70 (2H, 
m), 2.70 – 2.56 (2H, m), 2.52 (3H, s, H-5), 2.28 – 2.11 (2H, m), 1.99 (1H, t, J = 11.3 Hz), 1.81 (1H, 
s, NH), 1.15 (1H, q, J = 12.2 Hz); δC(100 MHz, CDCl3): 133.54, 132.59, 129.39 (2C), 128.50 (2C), 
122.70, 122.46, 112.57, 110.76, 106.72, 67.65, 62.28, 53.55, 53.28, 43.28, 40.59, 36.14, 32.77, 
26.97; LRMS (EI+): m/z = 392.95 (100.0%) [M+] calculated for C24H28Cl3N3 393.20 [M
+]; HPLC 
Purity: 99% (tr = 12.42 min). 
5.8 Testing protocols 
5.8.1 Antimycobacterial Testing protocol 
The MIC99 was determined using a standard broth microdilution method,
82,83 where a 10 ml 
culture of Mycobacterium tuberculosis,84 H37Rv strain was grown to an OD600 of 0.6 – 0.7. The 
culture was then diluted 1:500 in liquid 7H9 medium, and 50 μl of 7H9 medium was added. The 
compounds to be tested were added in duplicate, at a final concentration of 640 μM (stocks 
were made up to a concentration of 12.8 mM in DMSO, and diluted to 640 μM in 7H9 medium). 
A two-fold serial dilution was prepared; finally, 50 μl of the 1:500 diluted M. tuberculosis 
culture was added. Controls used were media only, 5 % DMSO, Rifampicin and Kanamycin. The 












evaporation of liquid. The lowest concentration of drug that inhibits growth of more than 99 % 
of the bacterial population was considered to be the MIC99. MIC99 values were scored visually at 
days 7 and 14 post inoculation, and digital images captured and stored. 
5.8.2 Antiplasmodial Testing Protocol 
The compounds were tested in triplicate against chloroquine sensitive (CQS) strain of 
Plasmodium falciparum (NF54). Continuous in vitro cultures of asexual erythrocyte stages of P. 
falciparum were maintained using a modified method of Trager and Jensen.85 Quantitative 
assessment of in vitro antiplasmodial activity was determined via a modified parasite lactate 
dehydrogenase assay as described by Malker.86 The test samples were prepared as a 20 mg/ml 
stock solution in 100% DMSO and sonicated to enhance solubility. Stock solutions were stored 
at -20ºC and further dilution were prepared on the day of the experiment. Samples were tested 
as a suspension if not completely dissolved. Chloroquine (CQ) was used as the reference drug in 
all experiments. A full dose-response was performed for all compounds to determine the IC50 
value which is the concentration inhibiting 50% of parasite growth. Test samples were tested at 
a starting concentration of 10 μg/ml, which was then serially diluted 2-fold in complete medium 
to give 10 concentrations; with the lowest concentration being 0.02 μg/ml. The IC50-values 
were obtained using a nonlinear dose-response curve fitting analysis via Graph Pad Prism v.4.0 
software. 
5.8.3 Cytotoxicity Testing Protocol 
The compounds were tested for in vitro cytotoxicity against a mammalian cell-line, Chinese 
Hamster Ovarian (CHO), using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 
(MTT)-assay. The MTT-assay is used as a colorimetric assay for cellular growth and survival.87,88 
The tetrazolium salt MTT was used to measure all growth and chemosensitivity. The test 
samples were tested in triplicate on one occasion. The test samples were prepared to a 2mg/ml 
stock solution in 10% methanol or 10% DMSO and were tested as a suspension if not properly 
dissolved. Test compounds were stored at -20ºC until use. Emetine was used as the reference 
drug in all experiments. The initial concentration of emetine was 100 μg/ml, which was serially 












0.001μg/ml. The same dilution technique was applied to the all test samples. The 50% 
inhibitory concentration (IC50) values were obtained from full dose-response curves using a 
non-linear dose-response curve fitting analysis via GraphPad Prism v.4 software. 
5.8.4 Turbidimetric Solubility Assay protocol 
0.01M pH 7.4 Phosphate Buffered Saline (PBS) was prepared by dissolving 1 intact PBS buffer 
tablet in sufficient distilled water to make 1000 ml of a solution comprising 0.14M NaCl, 0.003M 
KCl and 0.01M phosphate buffer. This solution was filtered through a 0.22 μM nylon filter to 
remove any particulate contaminants and the pH ascertained using a pH meter. 10mM stock 
solutions of the test samples were prepared by accurately weighing and dissolving each 
compound in sufficient DMSO to approximately 1000 μl final volume. For each stock solution 
pre-dilutions of the compounds in DMSO were prepared in triplicate to yield concentrations 
from 0 to 10mM. From each pre-dilution solution, secondary dilutions of the compounds in 
both DMSO and 0.01M pH 7.4 PBS were prepared in a 96-well plate, in triplicate. The final 
volume of solvent in each assay plate well was 200 μl, prepared by pipetting 4 μl each of 
solution from the pre-dilution plate to the corresponding well into both DMSO and PBS (both 
196 μl). This ensured that the final concentration of DMSO in the PBS aqueous buffer did not 
exceed 2 % v/v. The different concentrations in DMSO were prepared to serve as controls to 
determine potential false turbimetric absorbance readings arising from the compounds in 
solution absorbing incident radiation at the analysis wavelength. The plate was then covered 
and left to equilibrate for 2 hours at ambient room temperature. UV-Vis absorbance readings 
from the plate were then measured at 620 nm. Corrected absorbance readings at different 
concentrations of test compounds were calculated by subtracting absorbance of the blank (i.e. 
DMSO and 1 % DMSO in PBS) from each subsequent concentration’s absorbance.89–93 
5.8.5 Microsomal Metabolic Stability Protocol 
0.40 mg protein/ml microsomes (pooled human mixed gender, male rat IGS, male mouse 
BALB/c) from XenoTech were incubated with 1 µM test compound at 37oC. Metabolic reactions 
were initiated by the addition of the co-factor NADPH and incubated for 30 minutes. The 












internal standard. The centrifuged and filtered samples were analysed by HPLC-MS/MS to 
determine the remaining concentrations of the test compounds. Control standards (midazolam 
and propranolol) were included in the assay to provide quality control and an indication of the 
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